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A Novel Approach To Antiplatelet Therapy: Targeting Protease Activated  
Receptor 4 
By 
MICHELE MARIE MUMAW 
Abstract 
Protease activated receptors (PARs) are seven transmembrane G-protein coupled 
receptors that are activated by cleavage of their N-terminus by a protease. Upon cleavage 
of their N-terminus, the new N-terminus acts as a tethered ligand for the receptor.  The 
ligand then binds to the corresponding receptor activating it. In the case of human 
platelets, which express PAR1 and PAR4, PAR cleavage by thrombin leads to signaling 
through Gq and G12/13 which causes numerous downstream intracellular effects in platelet 
activation including shape change, intracellular calcium release, secretion, and 
aggregation. To date the majority of PAR studies on platelets have focused on PAR1; 
however, PAR1 and PAR4 have distinct and overlapping signaling functions and affect 
the activation of one another. To more clearly understand the roles of PAR4 and to better 
understand the interplay between the two receptors, three main studies were conducted. 
First, heterodimerization of PAR1 and PAR4 was examined in detail. Secondly, studies 
were performed to evaluate the viability of targeting the anionic cluster on the N-
terminus of PAR4 as an antiplatelet therapy target. Finally, PAR4 monoclonal antibodies 
were developed which are able to detect PAR4 expression and activation on human 
platelets. 
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Chapter 1 : Introduction and Background 
Acute coronary syndromes (ACS) are one of the leading causes of death worldwide. The 
current standard for treatment of ACS is a combination therapy of aspirin and a P2Y12 
antagonist that decreases the risk of reoccurrence. However, the current treatment 
regimen has a number of limitations; most significantly, patients still experience 
cardiovascular events and additionally have an increased bleeding risk. This study 
examines protease activated receptor 4 (PAR4), a G-protein coupled receptor expressed 
on human platelets that has limited tissue distribution and is necessary for stable clot 
formation, as a new antiplatelet therapy target. Overall, this study identifies a novel target 
region on PAR4 (the anionic cluster on PAR4’s exodomain), provides insight toward 
developing future PAR antagonists based on the mechanism of thrombin binding to 
PAR4, and demonstrates the attractiveness of PAR4 as an antiplatelet therapy target that 
prevents cardiovascular events while having limited effect on hemostasis. 
 
1.1 Hemostasis 
Hemostasis is the process essential for arresting bleeding from a damaged blood vessel. 
Through the tightly regulated components of the hemostatic system, blood is converted 
from a liquid state to a gel like state at the site of injury, damaged blood vessels are 
plugged, and blood clots are removed following repair.  Hemostasis is a multicomponent 
process composed of coagulation, fibrinolysis, and platelet activation that is highly 
conserved through evolution [1].  
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1.1.1 Coagulation 
The Coagulation Cascade 
Following damage to the endothelial lining of a blood vessel the process of coagulation 
begins.  The coagulation pathway was named the coagulation cascade since the 
sequential activation of each clotting factor converts the next factor in the process from a 
zymogen, an inactive enzyme precursor present in circulation, to their active form [2, 3].  
The coagulation cascade consists of 1) the extrinsic pathway, activated following damage 
to the endothelium and the exposure of tissue factor (TF) on sub-endothelial cells, 2) the 
intrinsic pathway, in which all of the factors are present in the blood, and 3) the common 
pathway where the intrinsic and extrinsic pathways overlap (Figure 1.1A) [4].  The 
ultimate goal of the coagulation cascade is to generate thrombin that can both activate 
platelets and cleave fibrinogen to generate fibrin. 
 
The extrinsic pathway, composing the initiation phase of coagulation, is activated 
following damage to the endothelium that exposes the subendothelial matrix and the 
transmembrane receptor TF [5]. TF acts as a cofactor and binds FVII promoting 
conversion to the active form FVIIa. Together the TF/FVIIa complex cleaves FX into 
active FXa.  Following activation FXa interacts with FVa to form the prothombinase 
complex which converts II (prothrombin) into IIa (thrombin).   
 
Also known as the contact pathway, the intrinsic pathway is essential for the propagation 
phase of coagulation [1]. The intrinsic pathway is initiated by FXII activation on a 
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charged surface. FXIIa then activates FXI to FXIa which subsequently converts FIX to 
FIXa. Thrombin generated from extrinsic pathway activates VIII, VIIIa. FIXa and VIIIa 
then form the tenase complex which converts FX to FXa and feeds into the common 
pathway. 
 
Both the extrinsic and intrinsic pathways lead into the common pathway that starts with 
FX.  In the common pathway, FXa and FVa convert prothrombin (Factor II) to thrombin 
(Factor IIa). Thrombin has a wide range of functions from converting fibrinogen to fibrin 
which with platelets forms a hemostatic plug, activates factors FV, FVIII, FXI and FXIII, 
and is a potent platelet activator. Ultimately, the large quantity of thrombin generated 
produces fibrin fibers that are crosslinked to one another by FXIIIa to form a fibrin clot 
together with activated platelets (Figure 1.1B) [6]. 
 
Fibrinolysis 
Fibrinolysis removes excess fibrin from circulation to prevent unnecessary accumulation 
of fibrin and eventually, after healing of the blood vessel, lyses and degrades the formed 
thrombus [7].  Fibrinolysis is a tightly controlled multi-step process that converts the 
circulating zymogen plasminogen to the protease plasmin. Plasmin is the major protease 
responsible for degrading fibrin.  Plasminogen is converted to plasmin by both tissue 
plasminogen activator (tPA) and urokinase (uPA) [8]. tPA is secreted from endothelial 
cells and uPA is secreted from  monocytes, macrophages, and the urinary epithelium [7, 
8]. Plasmin then degrades fibrin to generate fibrin degradation products (Figure 1.1C) [7]. 
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In the specific situation wherein plasmin degrades fibrin cross-linked by FXIIIa, plasmin 
cleaves the C-terminal region of the α and β chains in the D-domain which is followed by 
proteolysis of the connecting region between the D and E domains. One of the resulting 
degradation products, a D-dimer, is formed composed of two D domains (Figure 1.1B) 
[9].  Since D-dimers are formed only when the fibrinolytic system is active, a D-dimer 
assay was developed to diagnose disease states such as deep vein thrombosis, pulmonary 
embolism, and cancer-associated thrombosis [10-13].  
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Figure 1.1: Coagulation and Fibrinolysis.  
A) The coagulation cascade is a multistep process composed of the extrinsic pathway, the 
intrinsic pathway, and the common pathway.  The extrinsic pathway is responsible for the 
initial burst of thrombin generation following trauma leading to exposure of tissue factor. 
The intrinsic pathway amplifies thrombin generation. Together the extrinsic and intrinsic 
pathways feed into the common pathway which ultimately results in thrombin generation. 
Thrombin cleaves fibrinogen to generate insoluble fibrin that is cross-linked to generate 
fibrin strands and forms a clot with platelets. B) Fibrinogen is cleaved by thrombin to 
release fibrinopeptide A and B generating fibrin. Fibrin then forms a fibrin polymer that 
is crosslinked by FXIIIa.  Plasmin cleaves fibrin to generate fibrin degradation products 
including D-dimers. C) In fibrinolysis plasminogen is converted to its active form, 
plasmin, by tPA and uPA.  Plasmin then cleaves fibrin to generate fibrin degradation 
products. 
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Figure 1.1: Coagulation and Fibrinolysis 
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1.1.2 Platelets 
Platelets are small anucleate discoid cells (~3.0 x 0.5 µm) produced from megakaryocytes 
which have a lifetime of approximately 7-10 days.  The primary role of platelets is to 
maintain hemostasis; however, they have been shown to play a role in tumor growth and 
metastasis, inflammation, angiogenesis, antimicrobial host defense, and glomerular 
disease. Two-thirds of platelets in humans circulate in the blood while the other third 
remains sequestered in the spleen.  Under normal conditions, platelets circulate in the 
blood in an inactive state and only become activated when they encounter damaged 
endothelium. At the site of a vascular injury, the subendothelial matrix is exposed which 
initiates platelet activation. Upon encountering damaged endothelium, platelets follow 
three steps to maintain hemostasis: adhesion, activation, and aggregation. 
 
1.2 Platelets  
1.2.1 Platelet Structure 
The structure of platelets plays a crucial role in maintaining their discoid shape when in 
an inactivate state and controlling the dramatic morphologic changes that platelets 
undergo when activated. The platelet structure is composed of a number of structural 
elements: an open canalicular system, a dense tubular system, a spectrin and actin based 
cytoskeleton, a microtubule coil, and granules. 
 
Open canalicular system 
The open canalicular system (OCS) is a network of tunnels that start at the plasma 
membrane of the platelet and travel throughout the interior of the platelet. The OCS is 
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necessary for three different functions of platelets. First, it is a semi-selective conduit 
which allows small external molecules to enter into the platelet and the release of the 
content from granules. Second, the lipid content of the OCS serves as a reservoir of 
internal membrane that can be used for filipodia formation and platelet spreading. Third, 
the OCS is a storage location for plasma membrane glycoproteins in which the proteins 
are sequestered or released following platelet activation by agonists [14, 15].  
 
Dense tubular system 
The dense tubular system (DTS) is formed from the smooth endoplasmic reticulum of 
megakaryocytes [16]. It is the primary site of calcium storage in platelets.  In the DTS 
calreticulin binds to Ca2+ and sequesters it to help maintain the resting platelet Ca2+ 
concentration at 100 nm/L [17]. Once platelets are activated by an agonist such as 
thrombin, cytoplasmic calcium levels rapidly rise as Ca2+ is released from the DTS into 
the cytoplasm [18]. The rapid rise in intracellular calcium levels causes granule release, 
cytoskeleton reorganization, and the association of αIIbβ3 [15]. 
 
Spectrin and actin based cytoskeleton  
Together spectrin strands and actin filaments maintain plasma membrane integrity and 
provide structure that protects the disc shape of the resting platelet.  Spectrin strands line 
the inside of the plasma membrane and connect to long actin filaments to form a singular 
continuous structure [19]. Actin, the most abundant protein in platelets, is formed into 
linear filaments or kept in storage as a non-filamental form in resting platelets [20]. The 
filaments are crosslinked by filamin and α-actinin to form a stiff cytoskeleton [21]. 
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During platelet activation, the stored actin is converted to actin filaments which facilitate 
platelet spreading. 
 
Microtubule coil 
Located just below the plasma membrane, platelets contain a single microtubule of 
polymerized α-β tubulin dimers coiled 8-12 times [22]. The main function of the 
microtubule coil is to maintain the disc shape of resting platelets. Following platelet 
activation, the microtubule dissembles allowing spherical shape change. 
 
Dense granules 
The first secretory vesicles released in the process of platelet activation are dense 
granules. These small granules can be identified using electron microscopy by their 
electron-dense cores and are relatively low abundance granules, 3-8 dense granules per 
platelet [23, 24]. Dense granules contain small molecules such as ATP, ADP, serotonin, 
calcium, and catecholamines that are secreted following platelet activation and further 
enhance activation [25].  
 
Alpha granules 
The most abundant vesicle in platelets is the alpha granule. Alpha granules make up 
approximately 10% of the platelet volume and are responsible for storing both soluble 
and membrane bound proteins involved in platelet activation [26].  Following platelet 
activation, alpha granules fuse with the platelet plasma membrane to increase the overall 
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surface area of the platelet, transport membrane bound proteins to the plasma membrane, 
and release soluble proteins to further enhance platelet activation [27].  
 
Under basal conditions the majority of the membrane bound proteins contained in alpha 
granules are expressed on the platelet plasma membrane (integrins, immunoglobulin 
family receptors, leucine-rich repeat family receptors, tetraspanins, CD36, Glut-3) [28-
32]. Following fusion of alpha granules with the platelet membrane, the number of these 
receptors on the platelet membrane greatly increases enhancing their ability to aid in 
further platelet activation. Not all alpha granule membrane proteins are present on the 
surface of resting platelet surface; for example, P-selectin is only expressed on the 
platelet surface following alpha granule fusion with the platelet membrane [28].  
 
Alpha granules also release soluble proteins following platelet activation which further 
propagate hemostasis. For example, platelet-platelet and platelet-subendothelial 
interactions are enhanced by the release of fibrinogen and VWF, respectively [33, 34]. 
Components of the coagulation system are also stored and released from alpha granules 
[28, 35].  
 
1.2.2 Platelet Activation 
Adhesion 
Following vascular injury, platelets first adhere to the site of the damaged vessel. At the 
site of the damaged endothelium both von Willebrand factor (VWF) and collagen play a 
crucial role in platelet adhesion.  VWF is released from endothelial cells into circulation 
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as well as exposed on the damaged endothelium. Under high shear conditions, GPIb-V-
IX on the platelet surface binds to VWF linked by collagen to the subendothelial matrix 
of the vascular wall [36].  The transient GPIb-V-IX VWF interaction enables initial 
tethering to the damaged vessel wall and slows platelets which allows the second 
adhesion receptor, GPVI, to interact with collagen at the site of injury [37, 38].  Collagen 
bound GPVI activates downstream signaling events triggering platelet activation and 
more stable adhesion by collagen interacting with activated α2β1 [39-42].   
 
Activation 
As platelets adhere to the damaged endothelium they are activated by a myriad of 
pathways.  VWF binding to GPIb-V-IX activates downstream signaling causing integrin 
activation, calcium elevation, and eventually aggregation [43-46].  GPVI bound to 
collagen leads to integrin activation, granule secretion, and thromboxane A2 synthesis 
[47, 48].  
 
Platelets also express multiple receptors that are necessary for sustained platelet 
activation. Thrombin generated by the coagulation system is a potent platelet agonist 
which activates protease activated receptor 1 and 4 (PAR) on human platelets [49-55]. 
Thromboxane A2 is synthesized by activated platelets and binds to the thromboxane 
receptor (TXA2/PGH2) which further amplifies platelet activation [56]. Dense granules 
release ADP which binds to P2Y1 and P2Y12 that couple to Gq and Gi, respectively, to 
regulate mobilization of calcium and lead to a second wave of aggregation [57-60]. 
Secreted ATP binds to P2X1 to allow rapid influx of Ca2+ ions through the channel [61, 
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62]. Serotonin released from dense granules binds to the platelet serotonin receptor (5-
HT2A) which couples to Gq to induce calcium mobilization [63]. Platelet activation also 
leads to the release of additional proteins from alpha-granules and the activation of 
integrins that is vital for platelet aggregation. 
 
Aggregation 
The next step in thrombus formation is aggregation which is mediated by the platelet 
integrin αIIbβ3. On resting platelets, αIIbβ3 is maintained in a low affinity, inactive state. 
The activation of platelet membrane receptors (e.g. PAR1, PAR4, TXA2, P2Y1, and 
P2Y12), induces intracellular signals that convert αIIbβ3 to an active ligand-binding state 
[64-67]. This process known as inside-out signaling enables platelet-platelet interactions. 
In an active state, αIIbβ3 is able to bind with high affinity to multiple extracellular ligands 
which enable platelet-platelet adhesion and thrombus formation [68].  Fibrinogen is the 
main αIIbβ3 ligand, but the receptor also binds to VWF and fibronectin that bridge 
platelets and activate them further [69-74]. Following ligand binding to the extracellular 
portion of αIIbβ3, the receptors cluster and conformational changes occur to the 
cytoplasmic portion of the integrin to initiate signaling inside the platelet, outside-in 
signaling [75-78].  The signaling events triggered by outside-in signaling are necessary 
for cytoskeletal reorganization, granule secretion, aggregation, platelet spreading, and 
stable platelet adherence [79-83].     
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Figure 1.2: Platelet Activation 
Platelets initially adhere to the damaged endothelium through GPIb-V-IX interacting with 
VWF and GPVI and α2β1 interacting with collagen. Platelets then secrete ATP, serotonin 
(5HT), and ADP from dense granules which activate P2X1, 5-HT2A, P2Y1, and P2Y12. 
TXA is generated, secreted, and activates the thromboxane receptor. Thrombin generated 
from the coagulation cascade activates PAR1 and PAR4.  Together signaling from the 
receptors leads to platelet activation. αIIbβ3 is then converted to its active form, binds 
fibrinogen, and enables platelets to bind to one another and aggregate.  Simultaneously, 
fibrinogen is cleaved to insoluble fibrin which forms a clot with aggregated platelets. 
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Figure 1.2: Platelet Activation 
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1.3 Thrombosis 
Under normal healthy conditions the endothelium suppresses coagulation, platelet 
adhesion, platelet activation, and inflammation.  This is accomplished through expression 
of tissue factor pathway inhibitor, production of tissue plasminogen activator and 
thrombomodulin, and secretion of NO, prostacyclin, and IL-10 [84]. However, under 
certain pathological circumstances the endothelium no longer adequately inhibits 
coagulation, platelet activation, and inflammation to suppress the formation of a localized 
thrombus. This results in the formation of a blood clot inside a blood vessel, known as 
thrombosis. Depending on the location and composition of the thrombus, it is defined as 
arterial thrombosis or venous thrombosis. Arterial thrombi are located in arterial blood 
vessels and are mainly composed of platelets (“white thrombus”). Venous thrombi are 
located in veins and are mainly composed of fibrin and red blood cells (“red thrombus”). 
The preferred method for preventing arterial thrombosis is antiplatelet therapy while 
venous thrombosis is normally treated with anticoagulant therapy. 
 
Arterial Thrombosis 
Arterial thrombosis is typically caused as a result of atherosclerosis [85].  Atherosclerosis 
is defined as the formation of an atherosclerotic plaque.  The process of atherosclerosis is 
initiated by the accumulation of cholesterol-LDL in the intima of blood vessels.  This 
leads to the activation of endothelial cells which recruit monocytes and T cells. The T 
cells enhance atherosclerosis activity and progression [86]. The monocytes differentiate 
into macrophages which engulf the LDL and form foam cells which can release growth 
factors and cytokines that cause vascular smooth muscle cells to migrate to the intima, 
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produce extracellular matrix components, and contribute to the fibrous cap formation [87, 
88]. The macrophages with high lipid content undergo apoptosis and are removed by M2 
macrophages which can be stressed to cause macrophage death [89].  The dead 
macrophages release pro-inflammatory compounds, lipids, metalloproteinases, and 
platelet activating molecules which are contained within the plaque (Figure 1.3A) [89-
91]. 
 
Many different plaque characteristics contribute to rupture (plaque composition, location, 
sheer stress, vessel expansion). Following disruption of the plaque, pro-thrombotic 
molecules are exposed to blood triggering platelet adhesion, activation, and aggregation.  
Depending on the degree of stenosis and the size of the plaque, the newly formed clot can 
completely occlude the flow of blood at the site of rupture blocking blood from reaching 
downstream tissues and organs. For example, if a coronary vessel is occluded, a 
myocardial infarction (heart attack) results or if an artery to the brain is obstructed, a 
stroke occurs. Clots also can break off from the site of injury and travel in circulation to a 
smaller blood vessel to cause a thromboembolism.  
 
Venous Thrombosis 
In contrast to arterial thrombosis, venous thrombosis is the formation of a thrombus 
within the veins. Venous thrombosis occurs most often at sites where the vessel wall is 
altered, sheer stress is low, and there is hypercoagulability [92].  Depending on where the 
thrombus is located, it is associated with chronic diseases such as congestive heart 
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failure, respiratory insufficiency, cancer, recent surgery, or immobilization. If the 
thrombus dislocates and travels to the lungs, it can cause a life-threatening pulmonary 
embolism (Figure 1.3B).   
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Figure 1.3 Arterial and Venous Thrombosis 
A) The primary cause of arterial thrombosis is the rupture of an atherosclerotic plaque.  
The multiple components involved in arterial thrombosis are illustrated. Arterial thrombi 
are mainly composed of platelets. 
B) Venous thrombosis is triggered by abnormal blood flow, increased coagulability, and 
alterations in the vessel wall. Venous thrombi are mainly composed of red blood cells 
and fibrin. 
Figure adapted from Mackman, N. Nature. 2008 Feb 21; 451(7181): 914–918. 
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Figure 1.3: Arterial and Venous Thrombosis 
 
 
Mackman, N. Nature. 2008 Feb 21; 451(7181): 914–918. 
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1.4 Anti-thrombotic Therapies 
1.4.1 Anticoagulant Therapies 
Anticoagulants are a class of drugs that target different steps in the coagulation cascade to 
prevent the formation or activity of thrombin.  They can be broken down into four 
groups: warfarin, heparin, factor Xa inhibitors, and direct thrombin inhibitors.  Warfarin 
and heparin are the traditional anti-coagulants, but anticoagulants were expanded within 
the past few years to include newly developed anticoagulants, factor Xa inhibitors and 
direct thrombin inhibitors.  The new anticoagulants are as good as or better than the 
traditional anticoagulants; however, they currently do not have a reversal agent in case of 
emergency bleeding situations. All of the anticoagulants are associated with an increased 
bleeding risk. 
 
Warfarin 
Warfarin’s method of action is inhibition of the vitamin K-epoxide reductase, preventing 
the recycling of vitamin K and reduced vitamin K from vitamin K epoxide.  Normally γ- 
carboxylation of factors II, VII, IX, and X, which enables binding of the coagulation 
factors to a phospholipidic surface, is coupled to the oxidation of the reduced form of 
vitamin K to vitamin K epoxide [93].  However, without the recycling of vitamin K 
epoxide to vitamin K and reduced vitamin K, γ- carboxylation of the vitamin K 
dependent clotting factors cannot occur. This ultimately prevents the formation of the 
active form of factors II, VII, IX, and X which causes an anti-thrombotic effect [94].  
Since warfarin has a narrow therapeutic window, its effectiveness is influenced by 
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vitamin K consumption, and many commonly used drugs affect its metabolism, the 
internal normalized ratio (INR) needs to be closely monitored to maintain a safe dose of 
warfarin to prevent thrombosis while minimizing bleeding risk.   
 
Heparin 
Heparin is a glycosaminoglycan used for the treatment and prevention of thrombi formed 
from atrial fibrillation, venous thromboembolisms, and wide spread intravascular 
coagulation [94].  Following binding to antithrombin, heparin causes a conformational 
change which enhances the activity of antithrombin and increases the rate of inactivation 
of both Xa and IIa (thrombin) [95].  In some individuals, heparin-induced 
thrombocytopenia (HIT) occurs as a result of the formation of heparin antibodies against 
heparin bound platelet factor 4 (PF4). The heparin-PF4-IgG complex then activates 
platelets through their FcγIIa receptor which can cause thrombosis and thrombocytopenia 
[96]. In cases of HIT, alternate anticoagulant therapies need to be administered such as 
the new generation anticoagulants, FXa and direct thrombin inhibitors.  
 
Factor Xa Inhibitors 
Factor Xa inhibitors are part of the new group of anticoagulants developed to target a 
different point in the coagulation cascade. As the name indicates, factor Xa inhibitors 
target Xa, the first step in the common pathway.  Three direct Xa inhibitors (apixaban, 
rivaroxiban, and edoxaban) have been developed that bind to the active site of Xa and 
inhibit its activity [97, 98]. Factor Xa inhibitors are available as an alternate anticoagulant 
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in the case of HIT, as well as for treatment of venous thromboembolism and thrombi 
formed as a result of atrial fibrillation [99].  
 
Direct Thrombin Inhibitors 
Direct thrombin inhibitors can be broken down into two groups, parenteral and oral.  Two 
parenteral direct thrombin inhibitors (bivalirudin and argatroban) have been developed.  
Bivalirudin is a 20 amino acid polypeptide that binds to both the active site and exosite I 
of thrombin. Similar to bivalirudin, argatroban is also a polypeptide that binds to the 
active site of thrombin, however, it does not bind to exosite site I. Since administered 
intravenously, their onset of action is immediate, but they have short half-lives since they 
are polypeptides.  Both bivalirudin and argatroban are alternatives to heparin [100]. 
 
The orally available direct thrombin inhibitor, dabigatran, is administered as a prodrug 
which is hydrolyzed to its active form that binds the active site of thrombin [100].  Since 
its onset is faster than warfarin and has a similar half-life but will not be affected by 
vitamin K intake, dabigatran is an alternate therapy for long-term treatment of venous 
thromboembolism.   
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Figure 1.4: Anticoagulant Therapies 
There are 4 different types of anticoagulant therapies that target different factors in the 
coagulation cascade.  Warfarin inhibits vitamin K-epoxide reductase preventing the 
formation of active vitamin K dependent clotting factors, II, VII, IX, and X. Heparin 
binds to antithrombin (AT III) and increases the inactivation of Xa and IIa. Apixaban, 
rivaroxiban, and edoxaban (factor Xa inhibitors) bind to the active site of Xa and inhibit 
it from activating II. The direct thrombin inhibitors bivalirudin, argatroban, and 
dabigatran bind to the active site of IIa and inhibit its enzymatic activity. 
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Figure 1.4: Anticoagulant Therapies 
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1.4.2 Antiplatelet Therapies 
Antiplatelet therapies are a classification of drugs that target various pathways involved 
in platelet activation. Antiplatelet therapies are broken down into four groups based on 
the target of the therapy, aspirin, P2Y12 antagonists, αIIbβ3 antagonists, and PAR1 
antagonists. The current standard of care for treating acute coronary syndromes is dual 
antiplatelet therapy of aspirin and a P2Y12 antagonist.  However, a PAR1 antagonist, 
vorapaxar, just recently received FDA approval in 2014, and for a limited number of 
patients it is recommended as an addition to dual antiplatelet therapy to prevent 
cardiovascular death, myocardial infraction, and stroke. αIIbβ3 antagonists are only 
recommended for use in high risk patients who have low bleeding risk [101, 102]. 
Treatment with any of the antiplatelet therapies is associated with an increased bleeding 
risk. 
 
Aspirin 
Aspirin, acetylsalicylic acid, has become standard of care for treatment of cardiovascular 
disorders.  Aspirin’s mechanism of action is through inhibition of cyclooxygenase (COX) 
-1 and COX-2 [103, 104]. Aspirin irreversibly acetylates S529 on COX-1 changing the 
conformation of the active site so that it cannot bind arachidonic acid [103, 105, 106]. In 
the case of COX-2, aspirin acetylates S516 which results in the enzyme converting 
arachidonic acid to 15-R-hydroxyeicosateraenoc acid [106, 107].  Aspirin is able to 
irreversibly inhibit both enzymes preventing the synthesis of prostaglandins 
(Thromboxane A2, Prostaglandin I2, Prostaglandin E2, Prostaglandin D2, and 
Prostaglandin F2α) [108].  
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Of the prostaglandins produced from arachidonic acid, two have an effect on platelet 
aggregation, prostaglandin I2 (PGI2) and thromboxane A2 (TXA2).  Prostacyclin I2 is 
produced by the endothelium to inhibit platelet aggregation and maintain vasodilation 
[104]. In contrast thromboxane A2 has a proaggregation effect. In response to platelet 
agonists, platelets increase production of TXA2 which then amplifies aggregation further 
and stimulates vasoconstriction [109]. Since platelets express high levels of COX-1, the 
antiplatelet effect of aspirin occurs as a result of inhibiting COX-1 in platelets. In 
contrast, COX-2 is primarily responsible for PGI2 synthesis by the endothelium [104, 
110-112]. Since aspirin has a 170-fold greater inhibitory effect on COX-1 then COX-2, at 
low doses aspirin is able to irreversibly inhibit COX-1 on platelets preventing TXA2 
production for the lifetime of the platelet, but has a small temporary effect on PGI2 
production by COX-2 in the endothelium which ultimately provides the maximal effect 
for platelet inhibition [113-116].  
 
P2Y12 Antagonists 
Combination therapy of aspirin with a P2Y12 antagonist is the primary method of 
treating acute coronary syndrome (a decrease in blood flow to the heart). Currently, 
multiple P2Y12 inhibitors are available and approved by the FDA. Three of the inhibitors 
are thienopyridines, ticlopidine, clopidogrel, and prasugrel.  Ticlopidine was the first 
generated thienopyridine P2Y12 inhibitor which received FDA approval in 1991, 
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however, due to its toxic side effects (neutropenia and thrombocytopenia) a new drug 
with a better safety profile was developed, clopidogrel [117-119]. 
 
Clopidogrel is the most widely prescribed antiplatelet therapy since it has relatively low 
cost, a generic form of the drug has been available since 2012, and is highly effective 
[120, 121]. Clopidogrel is orally administered as a prodrug, metabolized by numerous 
CYP isoenzymes including CYP2C19, and the active metabolite irreversibly binds to 
P2Y12 to cause inhibition of ADP-induced platelet activation and aggregation [122]. 
However, there are limitations to clopidogrel administration since only 15% of the drug is 
converted to an active metabolite and there are common loss-of-function variants to 
CYP2C19 preventing individuals from receiving clopidogrel treatment [123]. 
 
Prasugrel is a third generation P2Y12 inhibitor that was developed to overcome some of 
the limitations associated with clopidogrel. Similar to clopidogrel, prasugrel is orally 
administered as a prodrug which following metabolism irreversibly inhibits P2Y12 [15].  
However, the majority of the prodrug is converted to the active metabolite and its 
metabolism does not appear to be affected by CYP variants [124, 125]. Since both 
prasugrel and clopidogrel irreversibly inhibit P2Y12, they are associated with a long half-
life because the platelet population must be replaced. 
 
Ticagrelor, the first non-thienopyridine inhibitor, is an orally active drug that reversibly 
binds P2Y12 [123].  Since the drug is administered in its active form, it overcomes the 
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metabolism issue associated with clopidogrel. In addition, Ticagrelor reversibly binds 
P2Y12 so it does not have a slow offset of action [126].  However, because ticagrelor is 
metabolized by CYP3A4 in the liver to be excreted, ticagrelor cannot be administered 
with other drugs that influence the activity of CYP3A4 [127].  Overall, treatment with 
any of the P2Y12 inhibitors is associated with increased bleeding risk. 
 
αIIbβ3 Antagonists 
Currently there are three FDA approved αIIbβ3 antagonists for treatment of acute 
cornonary syndromes, abciximab, tirofiban, and eptifibatide.  Unlike aspirin and P2Y12 
inhibitors which inhibit signal transduction leading to αIIbβ3 activation, αIIbβ3 antagonists 
directly block ligand binding to the receptor to prevent aggregation.  While three different 
approaches have been used to develop αIIbβ3 antagonists (abciximab is a murine-human 
chimeric Fab fragment, tirofiban is a nonpeptide small molecule designed after the RDG 
sequence, and eptifibatide is a KGD containing cyclic heptapeptide), they all bind 
reversibly to αIIbβ3 to prevent ligand binding [79, 128-131].  After the development of 
αIIbβ3 antagonists, P2Y12 antagonists were developed which have a better safety profile. 
As such, αIIbβ3 antagonists are only recommended for use in high risk patients who have 
low bleeding risk [101, 102]. 
 
Protease Activated Receptor 1 Antagonists 
Even with dual antiplatelet therapy of aspirin and a P2Y12 antagonist, major 
cardiovascular events still occur in patients receiving treatment.  Recent research has led 
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to the hypothesis that the residual risk may be due to thrombin-mediated platelet 
activation and two protease activated receptor 1 (PAR1) antagonists have been 
developed, vorapaxar and atopaxar. 
 
Vorapaxar is a synthetic-tricyclic 3-phenylpyridine analog of himbacine (an 
antimuscarinic agent) that is highly selective for inhibiting PAR1 [132, 133]. Through 
interacting with transmembrane domains 3, 4, 5, 6, and 7 as well as extracellular loops 2 
and 3 of PAR1, vorapaxar binds in a unique pocket of the receptor and the PAR1-
vorapaxar complex cannot be easily reversed [134].  This most likely accounts for its 
long half-life (126-269 h) and prolonged effect [135]. Two phase III clinical trials were 
recently completed, TRA-CER and TRA 2P-TIMI 50.  The TRA-CER trial evaluated the 
effect of vorapaxar vs placebo on patients with Non-ST segment elevation (partial 
occlusion of a coronary artery) acute coronary syndromes who were receiving standard of 
care therapy [136]. The trial found that vorapaxar had a modest effect on reducing 
thrombosis mediated coronary events, however, there was a significant increase in 
clinically important bleeding, including intracranial hemorrhage, and the trial was 
stopped after reaching a prespecified number of primary endpoints [136]. The TRA 2P-
TIMI 50 trial investigated the addition of vorapaxar vs placebo onto standard of care 
therapy in the secondary prevention of atherothrombotic disease [137]. Based on the 
TRA-CER trial results and a 25 month follow-up of patients, patients who had previously 
had a stroke were removed from the trial and it continued with myocardial infarction and 
peripheral artery disease patients [136, 138]. At the end of the TRA 2P-TIMI 50 trial 
vorapaxar was found to significantly lower the risk of cardiovascular death or myocardial 
31 
 
infarction, but it did increase the risk of moderate or severe bleeding, including 
intracranial hemorrhage [137].  As a result, the FDA approved vorapaxar to reduce the 
risk of cardiovascular death, heart attack and stroke, but it carries a black box warning to 
not be used in patients with a history of stroke, transient ischemic attack, intracranial 
hemorrhage, or active pathological bleeding. 
 
Atopaxar is another PAR1 antagonist that was under investigation as an antiplatelet 
agent. Similar to vorapaxar, atopaxar is orally available, potent, selective PAR1 
antagonist, but it is more rapidly reversible and as a result a shorter half-life (22-26h) 
[139-141].  Two atopaxar phase II trials were recently completed, J-LANCELOT and 
LANCELOT ACS, that raised safety concerns (liver toxicity and malignant arrhythmias) 
and showed low efficacy resulting in suspension of further evaluation of atopaxar [139, 
142].  
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Figure 1.5: Antiplatelet Therapies 
There are currently 4 different classes of antiplatelet therapies that are available for 
treatment of acute coronary syndromes that each inhibits platelet activation by different 
agonists. Aspirin inhibits thromboxane and PGI2 production by inhibiting COX-1 and 
COX-2. P2Y12 antagonists (ticlopidine, clopidogrel, prasugrel, and ticagrelor) prevent 
activation of the P2Y12 receptor by ADP. αIIbβ3 antagonists (abciximab, tirofiban, and 
eptifibatide) prevent the receptor from binding fibrinogen. Vorapaxar and atopaxar are 
PAR1 selective antagonists. 
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Figure 1.5: Antiplatelet Therapies 
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1.5 Protease Activated Receptors 
Protease Activated Receptors (PARs) compose a unique family of seven-transmembrane 
G protein-coupled receptors that contain their own ligand sequence that is revealed 
following proteolytic cleavage [143].  The PAR family is composed of four members: 
PAR1, PAR2, PAR3, and PAR4 that are expressed in many cell types including platelets, 
endothelial cells, immune cells, smooth muscle cells, fibroblasts, neurons, astrocytes, and 
microglia [144, 145]. Following cleavage of their N-terminus by a protease, the newly 
exposed tethered ligand is able to intramolecularly bind to the receptor and trigger 
signaling [143].  Additionally, PARs can be activated by peptides which closely mimic 
their tethered ligand sequence. Depending on the receptor subtype, the cell type, and 
location within the plasma membrane, PARs couple to numerous G protein subtypes (Gq, 
Gi, G12/13) [146] that activate various downstream signaling events (Figure 1.6). 
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Figure 1.6: Protease Activated Receptors 
Protease activated receptors are G-protein coupled receptors that are activated by 
proteolytic cleavage of their N-terminus by a protease.  Following cleavage, the new N-
terminus acts as a tethered ligand which intramolecularly activates the PAR and leads to 
downstream signaling through Gq, Gi, and/or G12/13. 
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Figure 1.6: Protease Activated Receptors 
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1.5.1 PAR1 
PAR1 was originally discovered as a result of searching for the receptor that mediates the 
response to thrombin [54].  Since PAR1 was the first PAR to be discovered it is 
considered prototypic and has been studied in the most detail.  PAR1 is widely expressed 
in human tissues, and in particular, is highly expressed in cells involved in hemostatic 
regulation [54, 147, 148]. PAR1 is predominantly activated by thrombin.  Thrombin 
interacts with high affinity to two sites on PAR1 and low nanomolar concentrations of the 
enzyme are necessary to activate the receptor. The active site of thrombin binds to the 
cleavage site (LPDR41↓SFLLRN) on PAR1 and thrombin’s anionic-binding exosite I 
interacts with the “hirudin-like” domain (residues 59-69) on PAR1 [149-151].  Following 
cleavage, the tethered ligand binds to PAR1 and triggers downstream signaling through 
Gq, Gi, and/or G12/13 depending on the cell type [152]. In addition to  cell type 
determining PAR1 signaling, the protease (thrombin, factor Xa, plasmin, kallikriens, 
activated protein C (APC), and matrix metalloprotease-1 (MMP1)) that cleaves PAR1 
can regulate signaling [146, 153]. For example, activation of PAR1 by thrombin in 
endothelial cells is permeability-enhancing whereas activation of PAR1 by APC is 
barrier-protective, and the localization of PAR1 in the plasma membrane regulates this 
effect [154-156].  
 
1.5.2 PAR2 
PAR2 is widely expressed in human tissues and particularly in the liver, kidneys, 
pancreas, small intestine, and colon [157]. Unlike the other PARs, PAR2 is not activated 
by thrombin, but instead it is activated by trypsin, tryptase, membrane-anchored 
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matriptase, factor VIIa, and factor Xa [146].  The proteases cleave the receptor at 
SKGR36↓SLIGK, and similar to other PARs, the receptor activates Gq, Gi, and/or G12/13 
depending on the cell type. In addition, PAR1 can modulate the activation of PAR2 by 
PAR1’s  tethered ligand binding intermolecularly and transactivating PAR2 [158]. 
 
1.5.3 PAR3 
In humans, PAR3 is less widely expressed than PAR1 and PAR2. It is only expressed in 
bone marrow and vascular endothelial cells [159]. Similar to PAR1, PAR3 contains a 
hirudin like sequence (F48EEFP) that facilities cleavage of the N-terminus at 
L35PIK↓TFRGAP, however, PAR3 is only cleaved by thrombin and APC [160, 161].  
PAR3 activates Gq to initiate signaling events [162]. 
 
1.5.4 PAR4 
PAR4 is the most recently discovered PAR family member. PAR4 is highly expressed in 
the lung, pancreas, thyroid, testis, small intestine, and platelets [55]. Similar to PAR1 and 
PAR3, PAR4 is activated following proteolytic cleavage by thrombin but requires a 
higher concentration of thrombin (EC50 5nM for PAR4 vs 0.2 nM for PAR1 and PAR3) 
to be activated [54, 55, 67, 159].  This is a result of the fact that PAR4 does not contain a 
hirudin like region, does not bind to exosite I, and therefore, cannot shift thrombin to a 
more active conformation through exosite I binding [163]. Instead, PAR4 contains an 
anionic cluster (D57, D59, E62, and D65) that interacts with thrombin’s autolysis loop and 
slows the dissociation of thrombin from PAR4 prolonging the interaction time between 
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PAR4 and thrombin so cleavage can occur at the thrombin cleavage site 
P44APR↓GYPGQV [55, 163-165]. In addition to being activated by thrombin, PAR4 can 
also be cleaved by trypsin or plasmin. Following activation, PAR4 signals through Gq, Gi, 
and/or G12/13. While PAR4 has been mainly studied in the context on platelets, the 
receptor has also been shown to play a physiological role in other tissues and disease 
states such as myocardial ischemia/reperfusion injury, joint pain, inflammation, and 
diabetes [166-171]. 
 
1.6 Protease Activated Receptors on Platelets 
1.6.1 Human Platelets 
Of the 4 PAR family members human platelets express PAR1 and PAR4 with PAR1 
more highly expressed than PAR4 [55]. In platelets, PAR1 and PAR4 have been shown 
to have unique and overlapping functions [172].  In the context of platelet activation, 
following cleavage of PAR1 or PAR4 by thrombin, both of the receptors signal through 
Gq and G12/13. Gq signaling in platelets results in activation of phospholipase C-β which 
ultimately increases intramolecular calcium concentrations to cause granule secretion, 
integrin activation, and aggregation [173]. G12/13 signaling ultimately leads to platelet 
shape change and granule secretion through activation of RhoA that activates Rho kinase 
that phosphorylates and inhibits myosin light chain phosphatase leading to enhanced 
myosin light chain phosphorylation and MLC-dependent contraction [174-177]. 
However, following thrombin activation in platelets, the two receptors have been shown 
to have differing roles on calcium release.  Initially, thrombin stimulation of PAR1 
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results in a rapid increase in intracellular calcium which is followed by a sustained 
calcium response controlled by PAR4 [66, 178]. The prolonged signal from PAR4 
activation has been shown to be necessary for stable clot formation [179, 180]. 
 
In addition to PAR1 and PAR4 signaling independently as monomers or homodimers, the 
receptors have been shown to form PAR1-PAR4 heterodimers [181-185]. Using 
bioluminescence resonance energy transfer (BRET), PAR1 was demonstrated to form 
constitutive homodimers [182].  Utilizing a similar approach of BRET and biomolecular 
fluorescence complementation (BiFC), PAR4 was shown to also form constitutive 
homodimers and this interaction is mediated through transmembrane helix 4 [183]. PAR1 
and PAR4 also form heterodimers and this allows PAR1 to act as a cofactor for 
thrombin-induced PAR4 activation [184, 185].  Coexpression of PAR1 with PAR4 
results in a ten-fold decrease in the EC50 for thrombin activation of PAR4 [165, 184].  
The current proposed model for PAR1 acting as a cofactor is that following PAR1 
cleavage by thrombin, the hirudin like region remains bound to exosite I of thrombin 
keeping it in the protease conformation [151, 186, 187].  An adjacent PAR4 is then able 
to interact with thrombin through its anionic region and the thrombin cleavage site can be 
more efficiently activated [165, 184, 188]. 
 
Furthermore, PAR4 has direct and indirect effects on P2Y12 signaling in platelets.  
Following activation, PAR4 and P2Y12 heterodimerize and recruit arrestin-2 to mediate 
PI3K-dependent AKT activation that affects platelet activation and stabilizes thrombi 
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[189, 190].  It has also previously been shown that PAR4 signals synergistically with 
P2Y12 to induce platelet activation [172]. 
 
Recently, it was determined that PAR4 contains polymorphisms at positions 120 
(Ala/Thr) and 296 (Phe/Val) [191-193]. The polymorphism at amino acid 120 is more 
common and is distributed by race. PAR4-120A is more often found in white individuals 
and is less reactive compared to PAR4-120T that is hyper reactive to agonists, resistant to 
a PAR4 antagonist, and found primarily in self-identified black individuals [191]. This 
correlates with a heritable interindividual variation in platelet reactivity observed to be 
higher in black individuals than white individuals [194-196]. The polymorphism at 296 
(Phe/Val) significantly decreases the activity of PAR4 which most likely accounts for 
valine at 296 being very uncommon. 
 
1.6.2 Mouse Platelets 
Mouse platelets express PAR3 and PAR4, however, PAR3 does not signal [67, 162, 197]. 
PAR activation of mouse platelets occurs only following PAR4 cleavage. On mouse 
platelets PAR4 signals through Gq and G12/13 which leads to platelet shape change, 
granule secretion, integrin activation, and aggregation. Similar to human PAR4, mouse 
PAR4 is not an efficient thrombin substrate and requires high concentrations of thrombin 
to induced platelet activation [162, 165, 198].  At low thrombin concentrations (< 10 
nM), mouse PAR3 acts as a cofactor for PAR4 activation, but at high thrombin 
concentrations (> 30 nM) PAR3 negatively regulates PAR4 Gq signaling without 
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affecting the G12/13 pathway [162, 199]. The formation of PAR3 homodimers, PAR4 
homodimers, and PAR3-PAR4 heterodimers may play a role in regulating the effect of 
PAR3 on PAR4 activation [199]. 
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1.7 Statement of Purpose 
Arterial thrombosis is responsible for the most deaths in the western world, yet there is an 
unmet need in decreasing major cardiovascular events while preventing clinically 
important bleeding. Platelets are a key component of pathological thrombosis.  As such, 
the current standard of care for acute coronary syndromes targets platelets with a 
combination of aspirin and a P2Y12 inhibitor.  While the current standard of care is 
effective at decreasing major cardiovascular events, they still occur and not all patients 
respond to combination therapy. As a result, antiplatelet therapy development shifted 
towards inhibiting thrombin activation of platelets.  
 
To date, protease activated receptor 1 (PAR1) is thought of as the primary thrombin 
receptor on platelets that is activated by lower thrombin concentrations. PAR4 is 
dismissed as the low-affinity, redundant, back-up thrombin receptor to PAR1. As a result 
PAR1 has been the focus for drug therapy development.  This has led to a detailed 
understanding of PAR1 activation resulting in a new antiplatelet therapy Zontivity 
(vorapaxar).  Therapy with Zontivity is limited by the fact that treatment is associated 
with an increase in clinically important bleeding, specifically intracranial hemorrhage.    
 
PAR1 and PAR4 have both overlapping and distinct properties.  Thrombin stimulation of 
platelets causes an initial rapid increase in intracellular calcium through PAR1 that is 
followed by a sustained calcium response controlled by PAR4.  The sustained calcium 
response initiated by PAR4 activation is necessary for stable clot formation. In addition, 
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it has been determined that the two receptors influence the activation and signaling of one 
another. Specifically, PAR1 and PAR4 form a heterodimer. Additionally, PAR1 lowers 
the EC50 of PAR4 activation ~10 fold. The exact mechanisms of how PAR1 and PAR4 
heterodimerize and how PAR1 is able to influence PAR4 activation are still unknown. 
 
The studies herein aim to 1) determine how the interaction between PAR1 and PAR4 
influences receptor activation, 2) examine the feasibility of PAR4 as an antiplatelet 
therapeutic target, and 3) develop PAR4 monoclonal antibodies to monitor or inhibit 
PAR4 activation in endogenous cells. 
 
(1) To define the functional relationship between PAR1 and PAR4, my thesis aimed to 
(a) map the heterodimer interface between PAR1 and PAR4, (b) determine if receptor 
cleavage is necessary for dimerization, and (c) examine if PAR1 assisted PAR4 
activation is dependent on heterodimer formation.   
 
(2) PAR4 is necessary for stable clot formation, has limited tissue distribution, and 
affects both thrombin and ADP signaling in platelets. My thesis aimed to determine if 
targeting a thrombin binding site on PAR4 (the anionic cluster) was a viable antiplatelet 
strategy. More specifically, I aimed to (a) develop a polyclonal antibody that interacted 
with PAR4’s anionic cluster, (b) determine its ability to inhibit human platelet 
aggregation, (c) and evaluate its effect on thrombosis and hemostasis.   
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(3) Currently, there are a limited number of reliable reagents for studying PAR4. My 
thesis aimed to (a) develop PAR4 monoclonal antibodies (b) determine if they are 
sensitive to PAR4 activation, and (c) evaluate their ability to inhibit PAR4 activation.  
 
In total, my thesis expands on the current understanding of how PAR1 and PAR4 interact 
and influence the activation of one another. It also demonstrates that PAR4 is a new 
viable target for antiplatelet therapy by preventing thrombosis without affecting 
hemostasis. In addition, these studies include the development of new tools that will 
enable studies that determine the role and function of PAR4 in endogenous cells and 
tissues.       
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Chapter 2 *†: 
 
Protease-activated Receptor 1 (PAR1) and PAR4 Heterodimers Are Required for 
PAR1-enhanced Cleavage of PAR4 by α-Thrombin 
 
2.1 Abstract 
Thrombin is a potent platelet agonist that activates platelets and other cells of the 
cardiovascular system by cleaving its G-protein-coupled receptors, protease-activated 
receptor 1 (PAR1), PAR4, or both. We now show that cleaving PAR1 and PAR4 with α-
thrombin induces heterodimer formation. PAR1-PAR4 heterodimers were not detected 
when unstimulated; however, when the cells were stimulated with 10 nM α-thrombin, we 
were able to detect a strong interaction between PAR1 and PAR4 by bioluminescence 
resonance energy transfer. In contrast, activating the receptors without cleavage using 
PAR1 and PAR4 agonist peptides (TFLLRN and AYPGKF, respectively) did not 
enhance heterodimer formation. Preventing PAR1 or PAR4 cleavage with point 
mutations or hirugen also prevented the induction of heterodimers. To further 
characterize the PAR1-PAR4 interactions, we mapped the heterodimer interface by 
introducing point mutations in transmembrane helix 4 of PAR1 or PAR4 that prevented 
heterodimer formation. Finally, we show that mutations in PAR1 or PAR4 at the 
heterodimer interface prevented PAR1-assisted cleavage of PAR4. These data 
demonstrate that PAR1 and PAR4 require allosteric changes induced via receptor 
                                                          
* A version of this chapter was accepted for publication in the November 8, 2013 issue of The Journal of 
Biological Chemistry. 
† I was a secondary author on this manuscript and my effort is detailed at the end of this chapter in 2.6 
Effort. 
47 
 
cleavage by α-thrombin to mediate heterodimer formation, and we have determined the 
PAR1-PAR4 heterodimer interface. Our findings show that PAR1 and PAR4 have 
dynamic interactions on the cell surface that should be taken into account when 
developing and characterizing PAR antagonists. 
 
2.2 Introduction 
Protease-activated receptors (PARs) are a unique class of G-protein-coupled receptors 
that are activated by proteolytic cleavage of the N terminus by serine proteases [144]. 
There are four members of this family (PAR1-4). In the cardiovascular system, PARs are 
expressed in platelets, leukocytes, endothelial cells, and smooth muscle cells where they 
play an important role in hemostasis, thrombosis, inflammation, proliferation, and cell 
permeability [144, 200]. 
 
PAR1 has multiple roles on many cell types. One example of its diverse signaling is on 
endothelial cells where it can have barrier protective or barrier disruptive roles depending 
on the agonist and co-receptors present on the cell [154, 155, 201, 202]. The majority of 
research on PAR1 has been conducted in the context of human platelet activation by 
thrombin. A Phase III clinical trial with a PAR1 antagonist, vorapaxar, as an antiplatelet 
agent did not meet its primary end point due to bleeding complications [136]. Recently, a 
crystal structure of PAR1 bound to vorapaxar was solved [134]. Vorapaxar bound deep 
within the transmembrane helices explaining the essentially irreversible nature of its 
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interaction with PAR1. However, the physical changes in PAR1 that occur after 
activation by thrombin have not been studied in detail. 
 
PAR4 is the primary signaling receptor on platelets of many species. In human platelets, 
PAR1 and PAR4 have both overlapping and unique signaling functions [172, 203]. For 
example, PAR4 activation produces a prolonged signal that is required for stable clot 
formation [66, 178-180]. Our laboratory has recently mapped the PAR4 homodimer 
interface to transmembrane helix 4 [183]. Mutations that disrupt PAR4 homodimers also 
disrupt Ca2+ signaling. On human platelets, PAR4 also interacts with PAR1 to enhance 
PAR4 activation [165, 184]. The details of this interaction are not known. 
 
The activation of PAR1 and PAR4 requires the receptors to be cleaved by thrombin. 
PAR1 is an excellent thrombin substrate [188, 204]. PAR1 has a hirudin-like sequence 
that binds tightly to thrombin exosite I [151]. Based on biochemical and structural data 
from other tight exosite I binders, the PAR1 hirudin-like sequence likely induces 
thrombin into the protease conformation [186, 187]. In contrast, PAR4 does not bind to 
exosite I and is a poor thrombin substrate when it is expressed on cells alone [163, 165]. 
The inefficient activation of PAR4 is overcome by co-expression of PAR1 on human 
platelets and PAR3 on mouse platelets [67, 184]. The proposed model for PAR1 or PAR3 
enhancing PAR4 activation is that after cleavage of PAR1 or PAR3, thrombin remains 
bound to the hirudin-like sequence via exosite I and cleaves an adjacent PAR4. In 
addition to recruiting thrombin to the surface of cells, the exosite I interaction is likely 
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holding thrombin in the protease conformation for efficient cleavage of PAR4 [162, 165, 
184]. The functional significance of PAR1 or PAR3 co-expression with PAR4 is a 10-
fold reduction in the EC50 of thrombin activation of PAR4 [162, 165, 184]. 
 
In addition to PAR1 and PAR4 having important independent roles in platelet signaling, 
the two receptors act synergistically by PAR1 enhancing PAR4 activation. To fully 
understand the relationship between PAR1 and PAR4, it is essential to have a complete 
understanding of the molecular arrangement and dynamics of their interactions. The 
present study demonstrates that α-thrombin promotes efficient heterodimerization 
between PAR1 and PAR4. The individual activating peptides for PAR1 and PAR4, 
TFLLRN and AYPGKF, respectively, and mutating the cleavage site of PAR1 or PAR4 
does not induce PAR1-PAR4 heterodimerization. The current study also defines the 
heterodimer interface and maps it to transmembrane helix 4 of both PAR1 and PAR4. 
Finally, mutations that disrupt PAR1-PAR4 heterodimerization also disrupt PAR1-
assisted cleavage of PAR4 by α-thrombin. Taken together, the current study defines the 
PAR1-PAR4 interaction and demonstrates a functional significance of the PAR1-PAR4 
heterodimer. 
 
2.3 Experimental Procedures 
Reagents 
Unless otherwise stated, all of the reagents were from Sigma. α-Thrombin was from 
Hematological Technologies (Essex Junction, VT). 
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Cell Culture 
HEK293, HeLa, and COS-7 cells were from American Type Culture Collections and 
were cultured in DMEM supplemented with 10% bovine serum albumin (Hyclone, 
Logan, UT) and 1% penicillin/streptomycin (Invitrogen). Cells were transfected with 
Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. 
 
Molecular Cloning 
The human PAR4 and the PAR4 transmembrane helix 4 mutants have been described 
(see Table 2.1) [183]. PAR4 with a mutation at the P1 residue of the thrombin cleavage 
site (PAR4-R47Q) was generated with overlapping PCR as previously described [188]. 
The nomenclature is that of Schechter and Berger [205] where the residue preceding the 
scissile bond is designated as P1. Human PAR1 in pLK-neo has been described and was 
the starting material for subsequent PCR reactions [165]. The HA tag (YPYDVPDYA) 
was added to the N terminus of the luciferase constructs, or V5 tag 
(GKPIPNPLLGLDST) was added to the N terminus of the GFP constructs at amino acid 
26 such that the PAR1 signal sequence was removed. Alanine substitution mutants of 
PAR1 were generated with overlapping PCR using primers that mutated the relevant 
codon(s) to change Arg-41 (PAR1-R41A), Phe-2214.44, Leu-2244.47, Trp-2274.50, and 
Ile-2314.54 (PAR1-TM4-4A), Trp-2274.50 and Ile-2314.54 (PAR1-W227A/I231A), or 
Val-2354.58 and Leu-2394.62 (PAR1-V235A/L239A) (Table 2.1). The numbering 
system is that of Ballesteros and Weinstein. For co-immunoprecipitation studies, a T7 tag 
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(MASMTGGQQMG) was added to the C terminus of wild type PAR4 using pcDNA3.1. 
HA-PAR1 wild type and HA-PAR1-W227A/I231A were expressed using pEF1α-IRES-
neo (Addgene), referred to as pEF1. For cleavage assays, V5-PAR4-wt or V5-PAR4-
TM4-4A was expressed using pIRES-puro (Addgene), referred to as pIRES. A detailed 
list of primers used for all cloning is available upon request. 
 
Bioluminescence Resonance Energy Transfer (BRET) 
Initial experiments determined the optimal expression of PAR1 for BRET experiments as 
previously described for PAR4 (15). HEK293 cells (1 × 105) were transfected with 
PAR1-GFP (0–1 μg) or PAR1-rLuc (0–0.5 μg) to determine the minimal amount of 
plasmid for sufficient GFP and luciferase signal. GFP was determined by excitation at 
495 nm and emission at 515 nm. Luciferase activity was determined using coelenterazine 
H (5 μM) and measuring total light emission without a filter in a PerkinElmer Life 
Sciences Victor 3 plate reader. The conditions that gave optimal expression for BRET 
studies were used in subsequent experiments. BRET experiments were performed as 
previously described [183]. To account for lower expression of PAR1, all PAR1-rLuc 
constructs were adjusted to 0.5 μg/transfection. PAR4-rLuc was used at 0.03 
μg/transfection as previously described [183]. The PAR4-GFP constructs were used at 0–
0.25 μg/transfection, and the PAR1-GFP constructs were used at 0–5 μg/transfection. The 
BRET data from three or four independent experiments were pooled and analyzed by 
global fit to all of the data using Prism software (GraphPad). The best model (hyperbolic 
versus linear) for each data set was also determined using Prism. The BRET50 values 
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were compared with an F test of the globally fit data with Prism; p < 0.05 was considered 
significant. 
 
Co-immunoprecipitation and Western Blot Analysis 
COS-7 cells in 10-cm plates were transiently transfected with PAR1-pEF1 (5 μg) and 
PAR4-T7-pcDNA3.1 (2 μg) or PAR1-pEF1 (5 μg) and PAR4-pcDNA3.1 (2 μg, no T7 
tag). Transfected cells were removed from plates 48 h post-transfection and washed twice 
with PBS. Cells were stimulated with 10 nM α-thrombin for 20 min at 37 °C and lysed 
with lysis buffer (1% Triton X-100, 50 mM Tris, pH 7.4, 100 mM NaCl, 5 mM EDTA) 
containing protease inhibitors mixture (Roche Applied Science) rotating 30 min at 4 °C. 
Proteins were extracted by centrifugation of lysed cells at 12,000 × g for 30 min at 4 °C. 
The supernatant-containing 300 μg of protein was immediately incubated with T7 
antibody-agarose (25 μl/sample, Novagen) and rotated at 4 °C overnight. Agarose beads 
were washed with 0.5× immunoprecipitation buffer three times, and the 
immunoprecipitated proteins were eluted with 0.1 M glycine, pH 2.6. Eluates were 
neutralized with Tris-HCl, pH 8.0, before adding 5× Laemmli reducing buffer. The 
samples were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride 
membranes. Membranes were incubated with anti-PAR1 (1: 333 dilution; WEDE15 
clone; Beckman Coulter) or anti-PAR4. Detection was performed with HRP-conjugated 
anti-mouse secondary antibody and an enhanced chemiluminescence system (Pierce). 
 
Cleavage Assays 
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To determine the influence of PAR1 mutations on the rate of PAR4 cleavage, COS-7 
cells in 10-cm plates were transiently transfected with HA-PAR1-pEF1 (0.5 μg) and V5-
PAR4-pIRES (2 μg), HA-PAR1-W227A/I231A-pEF1 (5 μg) and V5-PAR4-pIRES (2 
μg), or V5-PAR4-pIRES alone (2 μg). To determine the influence of PAR4 mutations, 
cells were transfected with HA-PAR1-pEF1 (5 μg) and V5-PAR4-TM4-4A-pIRES (2 μg) 
or V5-PAR4-TM4-4A-pIRES alone (2 μg). Transfected cells were removed from plates 
24 h post-transfection with versene, washed twice with PBS, and resuspended at 
concentration of 106 cells/ml in PBS. Reactions were initiated at 37 °C by adding 10 nM 
α-thrombin or 100 nM α-thrombin. Reactions were stopped at different time points with 
hirudin (0.5 units/ml), washed once with PBS, and incubated with V5 tag antibody 
conjugated to Alexa Fluor 647 (AbD Serotec) with a 1:50 dilution. The decrease of mean 
fluorescence as a result of the loss of the V5 epitope was determined by flow cytometry 
on a BD LSRFortessa (Center for Aids Research, Immune Function Core, Case Western 
Reserve University). The mean fluorescence data were fit to an exponential decay with 
the equation fl = fl0e−kt to compare the rate of PAR4 cleavage. The initial cell surface 
expression of HA-PAR1 and V5-PAR4 was determined by quantitative flow cytometry 
before adding thrombin using HA (Cell Signaling Technology Inc) or V5 antibodies 
conjugated to Alexa Fluor 647 with a 1:50 dilution and performed essentially as 
described [183]. 
 
Calcium Mobilization Assays 
HeLa cells were transfected with HA-PAR1-pEF1, HA-PAR1-W227A/I231A-pEF1, V5-
PAR4-pIRES, or V5-PAR4-TM4-4A-pIRES, and stable clones were selected with 
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puromycin (1 μg/ml) or Geneticin (1 mg/ml). Calcium mobilization was measured with 
Fura-2 as previously described [183, 199]. Briefly, cells were removed from plates with 
versene, washed, and loaded with 5 μM Fura2-AM (Invitrogen) in Hepes-Tyrodes buffer 
supplemented with magnesium and calcium. Cells (2.5 × 105) were placed into 96-well 
plates, stimulated with α-thrombin, and read in a NOVOstar plate reader (BMG Labtech, 
Durham, NC). Fluorescence measurements were converted to intracellular calcium 
concentration by the formula of Grynkiewicz et al. [206]. 
 
2.4 Results 
Previously, we determined the optimal conditions to analyze PAR4 homodimers by 
BRET using the minimal expression levels necessary to avoid overexpression artifacts 
[183]. Initial studies determined the minimal amount of plasmid to give sufficient PAR1-
rLuc expression was 0.5 μg (data not shown) compared with 0.03 μg for PAR4 [183]. 
The interaction between PAR1 and PAR4 was examined by BRET experiments that were 
designed to achieve similar levels of PAR1 and PAR4 expression. The initial experiments 
examined the PAR1-PAR4 heterodimer with BRET in unstimulated cells, which did not 
show a specific interaction, indicated by a linear relationship (Fig. 2.1A and Table 2.2). 
However, upon stimulation with 10 nM α-thrombin for 10 min there was a robust 
increase in the formation of PAR1-PAR4 heterodimers indicated by a hyperbolic curve 
(Fig. 2.1A and Table 2.2). The α-thrombin-induced interaction of PAR1 and PAR4 did 
not change when rLuc was fused to PAR1 and GFP was fused to PAR4 (Fig. 2.1B); the 
BRET50 (0.126 ± 0.08 versus 0.077 ± 0.03, p = 0.16) and BRETmax (0.17 ± 0.04 versus 
0.26 ± 0.03, p = 0.26) were both unchanged (Table 2.2). The specificity of the BRET 
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interaction was shown using the non-interacting GPCR rhodopsin (Fig. 2.1C). Similar to 
our previous studies with PAR4 [183], rhodopsin did not interact with PAR1. These data 
suggested that stimulation of the receptors with α-thrombin induced PAR1 and PAR4 to 
efficiently form heterodimers. 
 
Studies next determined if the induction of PAR1-PAR4 heterodimers was due to 
activation or cleavage of the receptor using PAR-activating peptides, PAR mutants, or the 
thrombin inhibitor hirugen. PAR1 and PAR4 activation peptides, TFLLRN or AYPGKF, 
respectively, can be used to activate the receptors in the absence of cleavage. Cells were 
prepared for BRET and stimulated with 50 μM TFLLRN and 500 μM AYPGKF 
simultaneously for 10 min. The PAR activation peptides did not induce PAR1-PAR4 
heterodimers (Fig. 2.2A). Stimulation of the cells with TFLLRN or AYPGKF 
individually also did not induce PAR1-PAR4 heterodimer formation (data not shown). To 
examine the requirement of PAR1 and PAR4 cleavage for the induction of heterodimers, 
the Arg in the P1 position of PAR1 or PAR4 was mutated and tested for its ability to 
form heterodimers. PAR1-R41A did not interact with PAR4 wild type after stimulation 
with 10 nM α-thrombin for 10 min (Fig. 2.2B). Similarly, the cleavage-deficient PAR4, 
PAR4-R47Q, did not interact with wild type PAR1 (Fig. 2.2C). Furthermore, blocking 
thrombin exosite I with hirugen also inhibited the induction of PAR1-PAR4 heterodimers 
(Fig. 2.2D). Flow cytometry with antibodies to the N-terminal tags HA or V5 on PAR1 or 
PAR4, respectively, confirmed that hirugen blocked the cleavage of PAR1 and PAR4 by 
thrombin (Fig. 2.2E). 
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PAR1 and PAR4 also form homodimers [182, 183]. In contrast to the PAR1-PAR4 
heterodimers, thrombin did not influence the BRET50 or BRETmax for PAR1 or PAR4 
homodimers (Fig. 2.3, A and B; Table 2). The BRET50 values were used to compare the 
relative affinities of α-thrombin-stimulated PAR1 homodimers, PAR4 homodimers, and 
PAR1-PAR4 heterodimers (Table 2.2). PAR4 homodimers had a lower BRET50 (higher 
relative affinity) (0.013 ± 0.01) compared with PAR1-PAR4 heterodimers regardless if 
the rLuc was fused to PAR4 (0.077 ± 0.026, p = 0.02) or PAR1 (0.126 ± 0.08, p = 0.01). 
PAR4 homodimers also had a lower BRET50 compared with PAR1 homodimers (0.159 
± 0.077, p = 0.01). Finally, the BRET50 for PAR1 homodimers and PAR1-PAR4 
heterodimers were not statistically different regardless if the pLuc was fused to PAR1 or 
PAR4 (p = 0.80 or 0.14, respectively). 
 
We next wanted to determine the PAR1-PAR4 heterodimer interface. We previously 
showed that the PAR4 homodimer interface is in transmembrane helix 4 (TM4) [183]. 
Therefore, we tested our panel of PAR4-TM4 alanine substitution mutants (Table 2.1) for 
the ability to associate with PAR1. The location of the mutations is shown in the 
molecular model of PAR4 that was generated by Swiss Modeler (Fig. 2.4A) [207-209]. 
Initial studies examined the surface expression with quantitative flow cytometry to ensure 
that each of the PAR4 mutants was expressed on the cell surface to the same degree as 
PAR4-wt (Fig. 2.4B). HEK293 cells were prepared for BRET assays and stimulated with 
10 nM α-thrombin for 10 min. PAR4-TM4-2A (PAR4-L209A/L213A) was able to 
interact with PAR1 similar to PAR4 wild type with a BRET50 of 0.057 ± 0.023, p = 0.30 
(Fig. 2.4C, Table 2.2). In contrast, PAR4-TM4-4A (PAR4-
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L192A/L194A/M198A/L202A) did not interact with PAR1, indicated by the linear 
relationship (Fig. 2.4D, Table 2.2). Residues in TM1 have also been reported to mediate 
GPCR dimers/oligomers [210, 211]. Therefore, we mutated four conserved residues in 
TM1 of PAR4 (Table 2.1) and tested their role in mediating the PAR1 interaction. PAR4-
TM1-4A (PAR4-L79A/V80A/L83A/L86A) interacted with PAR1 with the same 
BRET50 as PAR4 wild type (0.045 ± 0.040, p = 0.40) (Fig. 2.4E, Table 2.2). 
 
Next, we wanted to determine the interface on PAR1 for the PAR1-PAR4 heterodimer. 
We generated a model of PAR1 using Swiss Modeler to guide our mutagenesis studies 
[183, 207-209]. This PAR1 model revealed residues in TM4 that were directed away 
from the body of the receptor (Fig. 2.5A). A series of alanine substitution mutants in 
TM4 of PAR1 were generated to determine their association with PAR4 (Table 2.1). The 
surface expression of each of the PAR1 mutants was verified by quantitative flow 
cytometry (Fig. 2.5B). The PAR1 mutants were tested in BRET assays for their ability to 
interact with PAR4 wild type. Similar to PAR4, mutations in residues near the outer 
membrane, PAR1-V235A/L239A, did not disrupt the ability of α-thrombin to mediate 
PAR1-PAR4 heterodimerization; the BRET50 (0.034 ± 0.024) was not statistically 
different from PAR1-wt (p = 0.16) (Fig. 2.5C, Table 2.2). However, mutating two 
residues near the center of TM4, PAR1-W227A/I231A, disrupted the interaction with 
PAR4 indicated by the linear BRET curve (Fig. 2.5D). Mutating two additional residues 
also disrupted PAR1-PAR4 heterodimers (Fig. 2.5E). These data suggest that, like PAR4 
homodimers, several residues in TM4 of both receptors mediate the interaction between 
PAR1 and PAR4. Importantly, the residues in TM4 that mediate the PAR1-PAR4 
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interactions on both receptors (shown in orange in Figs. 2.4A and 2.5A) are in the same 
region along TM4 and align in a manner that would be capable of forming the interface. 
 
We next examined the ability of PAR1 and PAR4 mutants to induce intracellular 
signaling by measuring the calcium mobilization in response to α-thrombin (Fig. 2.6). 
Consistent with our previous results, HeLa cells do not respond to α-thrombin in calcium 
mobilization (Fig. 2.6C) [165]. When expressed on HeLa cells, PAR4-TM4-4A retained 
the ability to respond to 30 nM α-thrombin, however, with reduced efficiency compared 
with PAR4 (Fig. 2.6A). These data are consistent with our previous results [183]. 
Similarly, PAR1-W227A/I231A also retained the ability to induce intracellular calcium 
mobilization but at a reduced level compared with the PAR1 (Fig. 2.6C). We verified by 
flow cytometry that HA-PAR1-W227A/I231A and V5-PAR4-TM4-4A PAR4 mutants 
were expressed to the same level as HA-PAR1-wt and V5-PAR4-wt, respectively, on the 
surface of HeLa cells (Fig. 2.6, B and D). These data show that the PAR1 and PAR4 
mutants that disrupt the PAR1-PAR4 interface are expressed on the cell surface and have 
partial activity. 
 
To examine the PAR1-PAR4 interaction with a second technique, we co-expressed PAR1 
and PAR4 in COS-7 cells for co-immunoprecipitation studies. A T7 epitope was added to 
the C terminus of PAR4 to facilitate co-immunoprecipitation with anti-T7 agarose beads. 
PAR4 without a T7-epitope was used as a negative control. Cells expressing PAR1 and 
PAR4-cT7 were unstimulated or stimulated with 10 nM α-thrombin before lysis. We 
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were able to detect a specific interaction by co-immunoprecipitation with and without 
stimulation by α-thrombin (Fig. 2.7). To reliably detect the interaction with the co-
immunoprecipitation experiments, a 10-fold higher expression of PAR1 and PAR4 was 
required than for the BRET experiments. This may have contributed to the interactions in 
the unstimulated cells. Finally, the PAR4 lacking the T7 epitope also failed to co-
immunoprecipitate PAR1, indicating that PAR1 was not binding to the T7-agarose non-
specifically. 
 
In human platelets PAR1 serves as a cofactor for cleavage and activation of PAR4 at low 
thrombin concentrations (≤10 nM) (16, 17). In the previous studies we showed that PAR1 
lowered the EC50 of PAR4 cleavage by α-thrombin 6-fold when coexpressed on HeLa 
cells [165]. Therefore, we wanted to determine if PAR1-PAR4 heterodimers were 
required for PAR1-assisted PAR4 cleavage. To mimic the conditions that were used in 
the BRET assays, COS-7 cells expressing PAR4 alone or with PAR1 were treated with 
10 nM α-thrombin. Consistent with previous studies, PAR4 was not efficiently cleaved 
with 10 nM α-thrombin when expressed on cells alone (Fig. 2.8A, open circles). 
Coexpression of PAR1 increased the rate of cleavage (Fig. 2.8A, black circles). The rate 
constant (k) for PAR4 alone (0.006 ± 0.001) was 2.3-fold greater in the presence of 
PAR1 (0.014 ± 0.007 p = 0.03) (Table 2.3). Mutations in transmembrane helix 4 of PAR1 
that disrupt PAR1-PAR4 heterodimers did not enhance PAR4 cleavage (Fig. 2.8A, gray 
circles and Table 2.3). Quantitative flow cytometry was used to ensure that the initial 
PAR4 expression was the same in each of the experiments (Fig. 2.8E, black bars). The 
initial expression of PAR1 and PAR1-W227A/I231A was also verified by flow 
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cytometry (Fig. 2.8D, black bars). Disrupting PAR1-PAR4 heterodimers with PAR4 
mutations also abolished PAR1-assisted PAR4 cleavage (Fig. 2.8B). Coexpression of 
PAR1 did not influence the expression of PAR4-TM4-4A (Fig. 2.8E, dark gray bars). 
PAR1 was deliberately expressed at higher levels to confirm that the failure to increase 
the rate of PAR4 cleavage was not due to low expression of PAR1 (Fig. 2.8E, gray bars). 
Finally, we verified that PAR4-TM4-4A did not have intrinsic properties that made it less 
efficiently cleaved than PAR4 by increasing the α-thrombin concentration to 100 nM 
(Fig. 2.8C and Table 2.3). The disappearance of the V5 epitope was not due to 
internalization as PAR4-R47Q remained on the surface after stimulation with 100 nM α-
thrombin (data no shown). Taken together, these data suggest that PAR1-PAR4 
heterodimers are required for PAR1-assisted cleavage of PAR4. 
 
2.5 Discussion 
The current report shows that PAR1 and PAR4 form heterodimers that are modulated by 
α-thrombin. In contrast, the PAR1 and PAR4 activation peptides, TFLLRN and 
AYPGKP, respectively, were unable to induce heterodimers. We also show that 
cleavage-deficient mutants of PAR1 or PAR4 do not form heterodimers when stimulated 
with α-thrombin, confirming the requirement of receptor cleavage for heterodimerization. 
Additional experiments mapped the PAR1-PAR4 heterodimer interface to four residues 
in TM4 of both PAR1 and PAR4. Finally, mutations that disrupt PAR1-PAR4 
heterodimers also disrupt PAR1-assisted cleavage of PAR4 by α-thrombin. Taken 
together, our studies have defined the PAR1-PAR4 heterodimer and have linked these 
physical interactions to enhanced PAR4 cleavage by PAR1. 
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Our studies show that thrombin induces PAR1-PAR4 heterodimers with BRET. We have 
focused on BRET because it allows us to examine the PAR1-PAR4 interactions in living 
cells at near physiologic levels of expression (Figs. 2.4 and 2.5). Importantly, the levels 
of expression required for the BRET studies were sufficient to detect an enhanced rate of 
cleavage of PAR4 by PAR1 (Fig. 2.8). We were also able to show the PAR1-PAR4 
interactions with co-immunoprecipitation experiments (Fig. 2.7), which agree with Leger 
et al. [184]. However, we interpret our co-immunoprecipitation experiments with caution 
because the level of expression required for us to reliably detect PAR1 and PAR4 
interactions with this technique was 10-fold higher than required for the BRET and 
cleavage studies. Our interpretation is that at high expression levels, PAR1 and PAR4 can 
specifically interact in a thrombin-independent manner. Leger et al. [184] also showed 
PAR1 and PAR4 co-immunoprecipitation from human platelets that were stimulated with 
thrombin, which are in agreement with our BRET studies. However, we have not been 
able to co-immunoprecipitate PAR1 and PAR4 from human platelets using the antibodies 
available to us. 
 
The heterodimerization is specific to α-thrombin. This suggests that PAR1 and PAR4 
undergo specific allosteric rearrangement when stimulated with thrombin that is distinct 
from the activation peptides. This may be due to the conformational changes that must 
occur for the tethered ligand to activate the receptor after cleavage. The movement of the 
N terminus likely causes long-range conformational changes through the receptor that 
would not be required when the receptors are stimulated by the peptides that activate 
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PAR1 and PAR4 independently of receptor cleavage. An alternative explanation is that 
PAR1 and PAR4 form constitutive heterodimers and cleavage of the receptors results in 
the rearrangement of the C termini, which facilitates the detection of the BRET signal. 
The evidence against this interpretation is mutations that disrupt dimerization also disrupt 
PAR-1-assisted PAR4 cleavage. This will best be addressed by high resolution time-
resolved imaging techniques that are currently being developed [212]. A third possibility 
is that α-thrombin mediated the interaction by forming a trimolecular complex with 
PAR1 and PAR4. Our data in which α-thrombin pretreated with hirugen does not induce 
PAR1-PAR4 heterodimers suggests that the induction of PAR1-PAR4 heterodimers may 
be an exosite I-driven process (Fig. 2.2D). However, blocking exosite I also prevented 
cleavage of PAR1 and PAR4, which makes it difficult to separate the role of thrombin 
exosite I in efficient PAR1 cleavage and the potential cross-linking of PAR1 and PAR4. 
Finally, PAR1 and PAR4 may be differentially localized in the plasma membrane regions 
such as lipid rafts. Activation of the receptors may alter the interactions that PAR1 and 
PAR4 have with the membrane such that they are then able to interact with one another. 
Future studies will need to focus on the lipid environment and how it influences the 
protein-protein interactions. 
 
There are many studies that have examined the arrangement of GPCRs in the membranes 
of cells and synthetic membranes [213-216]. From these studies there is compelling 
evidence for both monomeric and dimeric/oligomeric receptors having functional 
significance. Recent studies using a minimal system of purified proteins and high density 
lipoprotein discs show that rhodopsin and β2-adrenergic receptors can functional as 
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monomers [213, 214]. For example, Whorton et al. [213] demonstrated that the 
monomeric β2-adrenergic receptor was able to mediate agonist-dependent nucleotide 
exchange from the Gs heterotrimeric G-protein. However, recent studies by Jastrzebska 
et al. [217, 218] demonstrated that bovine rhodopsin purified from native tissues is 
functional as a heteropentamer existing of two receptors in complex with a heterotrimeric 
G-protein. There is also structural evidence for GPCRs existing as dimers [219, 220]. 
Recently, a crystal structure of PAR1 bound to vorapaxar was solved [134]. The structure 
provides key details of the vorapaxar binding site on PAR1. However, the structural 
changes that occur upon PAR1 cleavage by thrombin are still unknown. Furthermore, the 
influence of other membrane proteins, such as PAR4, are also unknown. 
 
Many GPCR dimers are noncovalent, and the receptors are in equilibrium between 
monomers and dimers. An elegant study by Kasai et al. [221] has determined the two-
dimensional KD of the monomer to dimer transition for the N-formyl peptide receptor. In 
this study using single molecule fluorescence the authors determined that N-formyl 
peptide receptor monomers convert to dimers every 150 ms and the dimers dissociate to 
monomers every 91 ms with an overall average of 41% of the receptors in a dimer at any 
given time. These studies highlight the dynamic nature of membrane receptor dimers. 
Our results show that PAR1-PAR4 heterodimers are also dynamic in nature and can be 
induced by α-thrombin (Fig. 2.1). In contrast, PAR1 and PAR4 homodimers were not 
affected by stimulation with α-thrombin (Fig. 2.3). The question remains whether PAR1 
and PAR4 form dimers or oligomers. Our studies map the heterodimer interface to TM4; 
the same region that we have determined as the PAR4 homodimer interface [183]. 
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Therefore, our data suggest that PAR1 and PAR4 are in equilibrium between monomers 
and homodimers, and stimulating with α-thrombin induces the PAR1 and PAR4 
monomers to form heterodimers. The current study describes the conditions in which 
PAR1-PAR4 heterodimers efficiently form the interaction interface. These data will be 
essential for the development of quantitative studies to examine the stability of the 
homodimers compared with the heterodimers. An alternative hypothesis is that PAR1 
homodimers may interact with PAR4 homodimers to form higher order oligomers as has 
been described for other GPCRs [212]. 
 
The molecular arrangement of GPCRs on the cell surface has been studied for several 
receptors [216, 222]. The specific region that is involved in the dimer interface varies, but 
there are common themes that emerge. TM4 is a common interface for GPCRs to interact 
with one another [183, 211, 223, 224]. Our recent studies have mapped the homodimer 
interface for PAR4 to a region on TM4 [183]. Mutating Leu-2094.58 and Leu-2134.62 to 
alanine reduced PAR4 homodimer formation. Furthermore, mutating Leu-1924.41, Leu-
1944.43, Met-1984.47, and Leu-2024.51 to alanine completely disrupted the formation of 
PAR4 homodimers. In these studies, mutating single amino acids was not sufficient to 
disrupt PAR4 homodimers. A molecular model of PAR4 has this series of residues 
directed away from the body of the receptor and potentially available to mediate receptor 
dimers. We examined if these residues with outward facing side chains in TM4 of PAR4 
had a role in mediating PAR1-PAR4 heterodimers (Fig. 2.4A). In contrast to PAR4 
homodimers, mutating Leu-2094.54 and Leu-2134.62 did not disrupt PAR1-PAR4 
heterodimer formation in response to 10 nM α-thrombin (Fig. 2.4C). However, mutating 
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Leu-1924.41, Leu-1944.43, Met-1984.47, and Leu-2024.51 to alanine dramatically 
reduced the ability of PAR1 and PAR4 to interact in response to α-thrombin (Fig. 2.4D). 
These four residues are located near the cytoplasmic side to TM4 (Fig. 2.4A) and are also 
at the PAR4 homodimer interface [183]. Importantly, each of our mutants that disrupts 
heterodimer formation is expressed on the cell surface (Figs. 2.4B and 2.5B) and is 
capable of mediated Ca2+ mobilization (Fig. 2.6). The dopamine D2 receptor and α1β-
adrenoreceptor have been reported to form dimers/oligomers using residues in TM1 and 
TM4 [210, 211]. In our studies, mutating conserved residues in TM1 of PAR4 did not 
disrupt the formation of PAR1-PAR4 heterodimers (Fig. 2.4E). The residues in PAR1 
that mediate the PAR1-PAR4 heterodimer are also in TM4 (Fig. 2.5). These residues are 
also found near the cytoplasmic side of TM4 and align with the critical residues identified 
in TM4 of PAR4. In summary, our data suggest that PAR1-PAR4 heterodimer are 
arranged in the membrane at a TM4-TM4 interface. 
 
There are several GPCRs that have important signaling functions in platelets. We have 
described the dynamics of PAR1 and PAR4 heterodimers and have mapped the region for 
the interactions. Importantly, we have linked heterodimerization to PAR1-assisted PAR4 
cleavage. These data are in agreement with earlier studies by Nakanishi-Matsui et al. 
[162] that demonstrated that the exodomain of PAR1 was not able to enhance PAR4 
cleavage when fused to CD8 as it is unlikely that the PAR1-CD8 chimera is interacting 
with PAR4. PAR3 is well known to be a required cofactor of PAR4 activation on mouse 
platelets. We have recently shown that mouse PAR3 and mouse PAR4 form constitutive 
heterodimers and PAR3 negatively influences PAR4 signaling [199]. Previous studies by 
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Covic et al. [178] demonstrated that sequential activation of PAR1 and PAR4 on human 
platelets results in an increase in ADP response, which is dependent on PAR4. The 
sequential activation of PAR1 and PAR4 by thrombin may allow the receptors to 
rearrange in the platelet membrane and alter the signaling response. A recent study by Li 
et al. [189] described how PAR4 cooperates with the ADP receptor, P2Y12. In these 
studies platelets from arrestin-2-deficient mice had a reduction in Akt phosphorylation 
and fibrinogen binding in response to PAR4 activation. Li et al. [189] also showed that 
PAR4 physically interacts with the P2Y12 receptor in an agonist-dependent manner and 
may recruit arrestin-2 to PAR4. There is a complex arrangement of receptors and 
signaling molecules at the platelet surface in which PAR4 appears to be a common 
player. Future studies will need to examine how these and other GPCRs interact on 
platelets to mediate their full range of signaling in vivo. 
 
The current data show that the induction of heterodimers is specific to α-thrombin. PAR1 
and PAR4 both have distinct roles in platelet signaling. A recent Phase III clinical trial 
with the PAR1 antagonist vorapaxar that did not meet its primary end point underscores 
the need to fully understand the interactions between platelet receptors and how these 
interactions influence receptor function [136]. Future studies will need to generate 
models that can differentiate between heterodimer and homodimer signaling in platelets. 
The current work provides a framework for building platelet-specific models to examine 
the dynamics and signaling consequences of these interactions. In addition, understanding 
the molecular arrangement of PAR1 and PAR4 will provide insight for the development 
of antiplatelet therapies. 
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2.6 Effort 
As a secondary author on this paper, “Protease-activated receptor 1 (PAR1) and PAR4 
heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin”, 
published in JBC on November 2013, I contributed to the completion of this manuscript. 
HA-PAR1 wild type, HA-PAR1-W227A/I231A, V5-PAR4-wt, and V5-PAR4-TM4-4A 
were cloned and inserted into pEF1α-IRES-neo or pIRES-puro for the co-
immunopreciptation, immunoblotting, cleavage assay, and calcium mobilization studies.  
HeLa cells were transfected with HA-PAR1-pEF1, HA-PAR1-W227A/I231A-pEF1, V5-
PAR4-pIRES, or V5-PAR4-TM4-4A-pIRES, to generate stable clones used for the 
calcium mobilization studies. I performed the calcium mobilization studies and analyzed 
the data to determine the concentrations of calcium mobilized over time which were vital 
to answering reviewer comments and were included in the manuscript (Fig. 2.6). I also 
determined the surface expression of HA-PAR1, HA-PAR1-W227A/I231, V5-PAR4, and 
V5-PAR4-TM4-4A on the HeLa cells used for the calcium mobilization studies (Fig. 
2.6). In addition, I contributed to writing a section of the manuscript, aided in answering 
reviewer comments, and helped with editing the document.   
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Table 2.1: PAR1 and PAR4 transmembrane point mutations. Sequences are shown 
with standard one-letter abbreviations. Wild type sequences are shown in plain font. 
Mutated residues are shown in bold font and underlined. 
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Table 2.1: PAR1 and PAR4 transmembrane point mutations. 
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Table 2.2: BRET50 and BRETmax values for PAR1-PAR4 heterodimers. PAR4-GFP 
and PAR1-Luc were stimulated with the indicated agonist for 10 min and examined in 
BRET assays. The data were fit to a hyperbolic curve, and the BRET50 and BRETmax 
for each pair were calculated. Nonspecific interactions are indicated as linear. Values are 
compared to PAR1-rLuc/PAR4-GFP and PAR4-rLuc/PAR1-GFP interactions with an F-
test as described under “Experimental Procedures.” 
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Table 2.2: BRET50 and BRETmax values for PAR1-PAR4 heterodimers. 
 
  
72 
 
Table 2.3: Rate of PAR4 cleavage on cells. The rate of PAR4 cleavage by 10 or 100 nM 
α-thrombin was determined with COS7 cells expressing V5-PAR4 or V5-PAR4-TM4-4A 
by measuring the disappearance of an N-terminal V5 epitope. The influence of PAR1 was 
determined by co-expressing PAR1 or PAR1-W227A/I231A. 
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Table 2.3: Rate of PAR4 cleavage on cells. 
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Figure 2.1: Thrombin modulates PAR1-PAR4 heterodimer formation. HEK293 cells 
were transfected with HA-PAR4-rLuc (0.03 μg) and V5-PAR1-GFP (0–2.5 μg) (A), HA-
PAR1-rLuc (0.5 μg) and V5-PAR4-GFP (0–0.25 μg) (B), or HA-PAR1-rLuc (0.5 μg) and 
rhodopsin-GFP (0–1.5 μg) (C). Forty-eight hours post-transfection, the cells were 
unstimulated (solid circles) or treated with α-thrombin (10 nM) for 10 min (open circles). 
The cells were analyzed for GFP expression, luciferase activity, and BRET. The data are 
from three independent experiments in which all points were analyzed by global fit to 
hyperbolic or linear curve. 
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Figure 2.1: Thrombin modulates PAR1-PAR4 heterodimer formation. 
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Figure 2.2: PAR1 and PAR4 cleavage by thrombin is required to modulate 
dimerization. (A) BRET assays were performed in HEK293 cells expressing HA-PAR1-
rLuc (0.5 μg) and V5-PAR4-GFP (0–0.25 μg) after stimulation with TFLLRN (50 μM) 
and AYPGKF (500 μM) simultaneously for 10 min. HA-PAR4-rLuc (0.03 μg) and V5-
PAR1-R41A-GFP (0–2.5 μg) (B) and HA-PAR4-R47Q-Luc (0.03 μg) and V5-PAR1-
GFP (0–0.5 μg) (C) were analyzed by BRET assays after treatment with α-thrombin (10 
nM) for 10 min. (D) BRET assays were performed in cells expressing HA-PAR1-rLuc 
and V5-PAR4-GFP stimulated with α-thrombin (10 nM) pretreated with hirugen (10 
μM). For all BRET assays, GFP expression and luciferase activity were determined to 
calculate the GFP/rLuc ratio. The data are from three independent experiments in which 
all points were analyzed by global fit to hyperbolic or linear curve. E, the cleavage of 
HA-PAR1-rLuc or V5-PAR4-GFP by 10 nM α-thrombin pretreated with hirugen was 
analyzed by flow cytometry; error bars indicate S.D. of three independent experiments. 
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Figure 2.2: PAR1 and PAR4 cleavage by thrombin is required to modulate 
dimerization. 
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Figure 2.3: Thrombin does not modulate PAR1 or PAR4 homodimers. HEK293 cells 
were transfected with HA-PAR1-Luc (0.5 μg) and V5-PAR1-GFP (0–2.5 μg) (A) or HA-
PAR4-Luc (0.03 μg) and V5-PAR4-GFP (0–0.24 μg) (B). Forty-eight hours post-
transfection, the cells were unstimulated or treated with α-thrombin (10 nM) and 
analyzed for GFP expression, luciferase activity, and BRET. The data are from three 
independent experiments in which all points were analyzed by global fit to hyperbolic or 
linear curve. 
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Figure 2.3: Thrombin does not modulate PAR1 or PAR4 homodimers. 
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Figure 2.4: Residues in transmembrane helix 4 of PAR4 mediate interaction with 
PAR1. (A) Structural model of PAR4 based on rhodopsin generated with Swiss Modeler. 
TM1 is indicated in red, and TM4 is in blue. Residues that were analyzed in this study are 
shown as sticks. The residues in which alanine substitution disrupted α-thrombin-induced 
heterodimerization are shown in orange. The nomenclature is that of Ballesteros and 
Weinstein (27). (B) The expression of PAR4 wild type and mutants in HEK293 was 
analyzed by flow cytometry with an anti-V5 antibody. (C–E) BRET assays were 
performed in HEK293 cells expressing HA-PAR1-rLuc (0.5 μg) and V5-PAR4-TM4-2A-
GFP (C), V5-PAR4-TM4-4A -GFP (D), or V5-PAR4-TM1-4M-GFP (0–0.25 μg) (E). 
Forty-eight hours post-transfection, the cells were treated with α-thrombin (10 nM) for 10 
min and analyzed for GFP expression, luciferase activity, and BRET. The data are from 
three independent experiments in which all points were analyzed by global fit to 
hyperbolic or linear curve. 
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Figure 2.4: Residues in transmembrane helix 4 of PAR4 mediate interaction with 
PAR1.  
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Figure 2.5: Residues in transmembrane helix 4 of PAR1 mediate interaction with 
PAR4. (A) Structural model of PAR1 based on rhodopsin generated with Swiss Modeler. 
TM1 is indicated in red, and TM4 is in blue. Residues that were analyzed in this study are 
shown as sticks. The residues in which alanine substitution disrupted α-thrombin-induced 
heterodimerization are shown in orange. The nomenclature is that of Ballesteros and 
Weinstein (27). (B) The expression of PAR1 wild type and mutants in HEK293 was 
analyzed by flow cytometry with an anti-HA antibody. (C–E) BRET assays were 
performed in HEK293 cells expressing V5-PAR4-GFP (0-.24 μg) and HA-PAR1-
V235A/L239A-rLuc (C), HA-PAR1-W227A/I231A-rLuc (D), or HA-PAR1-TM4-4A-
rLuc (0.5 μg) (E). Forty-eight hours post-transfection the cells were treated with α-
thrombin (10 nM) for 10 min and analyzed for GFP expression, luciferase activity, and 
BRET. The data are from two or three independent experiments in which all points were 
analyzed by global fit to hyperbolic or linear curve. 
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Figure 2.5: Residues in transmembrane helix 4 of PAR1 mediate interaction with 
PAR4. 
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Figure 2.6: Thrombin-mediated intracellular calcium mobilization. HeLa cells 
expressing V5-PAR4 (black line) or V5-PAR4-TM4-4A (gray line) were loaded with 
Fura-2 in HEPES-Tyrode buffer, pH 7.4, containing 2 mM CaCl2 (A). Calcium 
mobilization was measured over time in response to 30 nM α-thrombin (indicated by the 
arrow) (A). The surface expression of V5-PAR4 or V5-PAR4-TM4-4A in the HeLa cells 
was determined by flow cytometry with a V5 tag antibody conjugated to AlexaFluor 647 
(B). Calcium mobilization was determined in HeLa cells expressing HA-PAR1 (black 
line), HA-PAR1-W227A/I231A (gray line), or parental HeLa cells (dashed line) as in 
panel A (C). MFI, mean fluorescence intensity. The surface expression of HA-PAR1 or 
HA-PAR1-W227A/I231A was determined by flow cytometry with an HA antibody 
conjugated to AlexaFluor 647 (D). 
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Figure 2.6: Thrombin-mediated intracellular calcium mobilization. 
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Figure 2.7: PAR1 and PAR4 co-immunoprecipitation studies. COS-7 cells were co-
transfected with PAR1 (5 μg) and PAR4-cT7 (2 μg) or with PAR4 (no cT7, 2 μg); cT7 is 
a C-terminal T7 epitope. Forty-eight hours post transfection, cells were harvested, 
stimulated with α-thrombin (10 nM), lysed, and incubated with T7-agarose overnight at 4 
°C. Co-immunoprecipitations (IP) were separated on SDS-PAGE and immunoblotted 
with anti-PAR1 or anti-PAR4. The space between lanes indicates samples run on the 
same gel in non-contiguous lanes, NS is nonstimulated. 
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Figure 2.7: PAR1 and PAR4 co-immunoprecipitation studies. 
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Figure 2.8: Dimerization is required for PAR1-assisted PAR4 cleavage by α-
thrombin. V5-PAR4 was expressed on COS-7 cells alone (open circles), with PAR1 
(black circles), or with PAR1-W227A/I231A (gray circles). PAR4 cleavage by 10 nM α-
thrombin was determined by measuring the loss of the V5 epitope over time by flow 
cytometry (A). V5-PAR4-TM4-4A was expressed on COS-7 cells alone (open circles) or 
with PAR1 (black circles), and the loss of the V5-epitope in response to 10 nM α-
thrombin was measured over time (B). V5-PAR4 (black circles) or V5-PAR4-TM4-4A 
(open circles) were expressed on COS-7 cells and treated with 100 nM α-thrombin (C). 
Quantitative flow cytometry was used to determine the expression of HA-PAR1 (black 
bar) or HA-PAR1-W227A/I231A (227/231) (dark gray bar) in the presence of V5-PAR4 
and HA-PAR1 expression in the presence of V5-PAR4-TM4-4A (P4-4A) (light gray bar) 
(D). Quantitative flow cytometry to determine V5-PAR4 expression in the absence or 
presence of PAR1 or PAR1-W227A/I231A (227/231) (black bars) and V5-PAR4-TM4-
4A (P4-4A) expression in the absence or presence of PAR1 (gray bars) (E). 
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Figure 2.8: Dimerization is required for PAR1-assisted PAR4 cleavage by α-
thrombin. 
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Chapter 3 ‡: 
 
Targeting the Anionic Region of Human Protease Activated Receptor 4 (PAR4) 
Inhibits Platelet Aggregation and Thrombosis without Interfering with Hemostasis. 
 
3.1 Abstract 
Background - Human platelet activation and aggregation is a complex process.  To date, 
many therapies have been developed targeting proteins that mediate this process to 
prevent unwanted activation.  However, the current standard of care for acute coronary 
syndromes still has limitations including bleeding risk. 
Objective - The aim of the current study is to evaluate the PAR4 anionic cluster as a 
viable antiplatelet target using a polyclonal antibody (CAN12). 
Methods - We used western blotting, aggregation, and secretion ex vivo to evaluate the 
ability of CAN12 to interact with PAR4 and inhibit platelet activation.  The effects of 
CAN12 in vivo were evaluated with the Rose Bengal arterial thrombosis model and two 
models of hemostasis. 
Results - We show that CAN12 is able to interact with human PAR4 and delay PAR4 
cleavage.  In addition, CAN12 inhibits thrombin induced human platelet aggregation and 
secretion in a dose dependent manner. We next determined that the specificity of CAN12 
is agonist dependent.  In vivo, we determined that CAN12 is able to inhibit arterial 
thrombosis and using two independent methods, we found that CAN12 does not 
influence hemostasis. 
                                                          
‡ A version of this chapter was accepted for publication in the August 2014 issue of the Journal of 
Thrombosis and Haemostasis. 
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Conclusion - Targeting the extracellular anionic cluster on PAR4 is a viable novel 
strategy as an antiplatelet therapy. 
 
3.2 Introduction 
Protease activated receptors (PARs) are G-protein coupled receptors activated by 
cleavage of their N-terminus by serine proteases.  There are four members of the PAR 
family: PAR1-4 [225].  PAR1, PAR3, and PAR4 are activated by thrombin, but PAR2 is 
activated by trypsin [226].  Upon cleavage of the N-terminus, the new N-terminus acts as 
a tethered ligand for the receptor [54, 227].  PAR activation initiates multiple 
downstream signaling events in platelets including activation of the small GTPase RhoA, 
intracellular calcium release, secretion, and a decrease in accumulation of cAMP through 
Gq, G12/13, and Gi [228-232].  The culmination of these events leads to platelet 
aggregation, and if uncontrollably activated, thrombosis.  
 
The current standard for the treatment of acute coronary syndromes by antiplatelet 
therapy is dual treatment with aspirin and a thienopyridine [233].  However, the current 
standard for treatment still has a number of limitations, most significantly, increased 
bleeding risk [234].  This has led to a need for better antiplatelet therapies. Additional 
therapies, such as glycoprotein IIb/IIIa and PAR1 inhibitors have been investigated as 
alternate antiplatelet therapies, but have had limited success [136, 235, 236].  
 
One innovative approach to antiplatelet therapies is targeting PAR4.  Specifically, near 
the anionic cluster on PAR4, D57, D59, E62, and D65, which is C-terminal of the thrombin 
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cleavage site at R47 [164]. The anionic cluster of PAR4 is crucial for thrombin interacting 
with the purified PAR4 exodomain and PAR4 expressed on cells [165, 204, 237]. The 
anionic cluster slows the dissociation of PAR4 from thrombin in a way that cleavage can 
occur [164, 165]. We propose that if this region is blocked so that thrombin cannot as 
easily bind and cleave PAR4, human platelet aggregation can be delayed. Therefore, the 
anionic region on PAR4 could be a potential therapeutic target. 
 
The current study examined a novel approach for antiplatelet therapy by targeting PAR4.  
We developed a goat polyclonal antibody that specifically targets the anionic cluster on 
PAR4. The antibody dose dependently inhibited thrombin induced human platelet 
aggregation and secretion.  In addition, we demonstrated that the antibody is able to 
prevent carotid artery thrombosis when administered before or after initiation of an 
injury. Interestingly, using two independent methods, we demonstrated that treatment 
with the antibody does not influence hemostasis in mice.  This study provides a new 
antiplatelet therapy target, the anionic region of PAR4, which could be a more efficacious 
approach for the treatment of acute coronary syndromes without the commonly 
associated increased bleeding risk. 
 
3.3 Material and Methods 
Reagents and Antibodies 
All cell culture reagents were purchased from Invitrogen.  Human α-thrombin was 
purchased from Haematological Technologies (specific activity 3200-3400 U/mg) (Essex 
Junction, VT).  PAR4 activating peptide (AYPGKF-NH2) and PAR1 activating peptide 
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(SFLLRN-NH2) were synthesized at PolyPeptide Laboratories (San Diego, CA). 
Convulxin was purchased from Enzo Life Sciences Inc. (Farmingdale, NY).  Collagen, 
ADP, and CHRONO-LUME were purchased from Chrono-log Corporation (Havertown, 
PA).  Protease inhibitor cocktail tablets were purchases from Roche. Rose-Bengal sodium 
salt, fibrinogen from human plasma, red blood cell lysing buffer, and sepharose 2B were 
purchased from Sigma-Aldrich.  The CAN12 antibody was prepared against the human 
PAR4 sequence (CANDSDTLELPD) by Bethyl Laboratories as a custom synthesis using 
a goat as the host.  The antibody was affinity purified using a CANDSDTLTLPD 
peptide-specific immunosorbent.  For control experiments, ChromPure goat IgG, whole 
molecule was purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, 
PA). The secondary antibodies IRDYE 800CW donkey anti-mouse IgG, IRDYE 680RD 
donkey anti-goat IgG, and IR 680RD goat anti-rabbit IgG were purchased from LI-COR 
Biosciences (Lincoln, NE). 
 
Animals 
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, Maine).  
F2RL3-/- mice (referred to as PAR4-/-) were obtained from the Mutant Mouse Regional 
Resource Center (MMRRC) (Chapel Hill, NC). All animal studies were approved by the 
Institutional Animal Care and Use Committee at Case Western Reserve University 
School of Medicine. 
 
Western blotting 
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HEK293 cells were purchased from American Type Culture Collection (Bethesda, MD) 
and were cultured in DMEM supplemented with 10% fetal bovine serum and 1% 
Pen/Strep.  Cells were transfected with Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions.  HEK293 cells were transfected with 1 µg mouse PAR4 or 
human PAR4.  After 48hrs, the cells were lysed in RIPA buffer (1% NP-40, 0.5% 
Deoxycholate, 0.1% SDS) on ice.  Following lysis, the lysate was collected and 
quantitated using the Biorad DC protein assay. 100µg of total protein was loaded and 
resolved by SDS-PAGE and transferred onto nitrocellulose. The membranes were 
incubated with primary goat antibody to CAN12.  To determine equal protein loading, 
the membrane was probed with rabbit antibody to α-actinin (1, 1000; Santa Cruz 
Biotechnology Inc.).  The membrane was developed using the Odyssey Infrared Imaging 
System.  The optical densities of proteins in the blot were quantified using software 
provided with the imaging system (Application Software version 3.0). 
For examining the CAN12 binding region of PAR4, HEK293 cells were transfected with 
4.0 µg human PAR4 or human PAR4-AAAA (D57A, D59A, E62A, D65A) [165]. The 
lysis and blotting procedure was the same as above. 
 
Cleavage assays 
HEK293 cells were transfected with HA-PAR1 (human) (4.0 µg) and V5-PAR4 (human) 
(0.1 µg) for 48 hours (described previously [185]).  Aliquots containing 1x106 cells were 
treated with PBS, IgG (2 µg/ml), or CAN12 (2 µg/ml) for 10 min and were activated with 
thrombin (100 nM) for 0, 2, or 30 min. The cells were then pelleted and lysed in RIPA 
buffer on ice.  Following lysis, the entire sample was resolved by SDS-PAGE and 
95 
 
transferred onto nitrocellulose for Western blotting with anti-V5-tag (1, 10,000; AbD 
Serotec.) and anti-α-actinin (1, 1000; Santa Cruz Biotechnology Inc.) as described above.   
 
PRP, Gel Filtered Platelets, and Washed Platelets Preparation 
Human platelets were obtained from healthy donors.  These studies were approved by the 
Case Western Reserve University Institutional Review Board and informed consent was 
obtained from all donors.  Whole blood was collected into the anticoagulant acid citrate 
dextrose (ACD) (2.5% sodium citrate, 71.4 mM citric acid, 2% D-glucose) and 
centrifuged at 200xg for 10 minutes at room temperature.  The platelet rich plasma (PRP) 
was used for aggregation experiments within 3 hours or used to generate gel filtered 
platelets as previously described [238].  Briefly, platelets were separated from plasma 
proteins using a sepharose 2B column in HEPES-Tyrode buffer pH 7.4 (10 mM HEPES, 
12 mM NaHCO3, 130 mM NaCl, 5 mM KCl, 0.4 mM Na2HPO4, 1 mM MgCl2, 5 mM 
glucose, 0.1% bovine serum albumin).  The number of platelets was quantitated using a 
Hemavet 950FS (Drew Scientific Inc, Waterbury, CT, USA).  
 
Mice were anesthetized by intraperitoneal injection of pentobarbital (62 mg/kg). Blood 
was collected by heparinized capillary puncture of the retro-orbital venous sinus and 
immediately combined with ACD (1/5). The whole blood was centrifuged at 2300xg for 
20 sec at room temperature to isolate the PRP. To pellet the platelets, the PRP was 
centrifuged at 2200xg for 3 minutes at room temperature.  The platelets were resuspended 
in HEPES-Tyrode buffer pH 7.4 (10 mM HEPES, 12 mM NaHCO3, 130 mM NaCl, 5 
mM KCl, 0.4 mM Na2HPO4, 1 mM MgCl2, 5 mM glucose, 0.33%  human serum 
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albumin). The number of platelets was quantitated using a Hemavet 950FS (Drew 
Scientific Inc, Waterbury, CT, USA).   
 
Aggregation 
Aggregation was measured using a lumi-aggregometer (Model 700, Chrono-log 
Corporation).  The sample was stirred constantly at 1200 RPM at 37°C.  Dense granule 
secretion was detected by ATP luminescence using CHROMO-LUME.  For all 
experiments, PRP, gel filtered platelets, or washed platelets were treated with HEPES-
Tyrode buffer, IgG (goat), or CAN12 for 10 minutes prior to activation with thrombin, 
AYPGKF, SFLLRN, ADP, collagen, or convulxin.  Aggrolink8 version 1.3.98 was used 
for data acquisition. The IC50 was determined using GraphPad Prism. 
 
Mouse Arterial Thrombosis Studies 
The arterial thrombosis experiments were performed using the Rose Bengal carotid artery 
thrombosis model, as previously described [239]. Saline, IgG (2 mg/kg), or CAN12 (1, 
0.5, 0.25, 0.125 mg/kg) was injected by tail vein into C57BL/6 mice 10 minutes before 
initiation of injury.  Alternatively, injury was initiated first and 15 minutes later IgG (2 
µg/ml) or CAN12 (0.5 mg/kg) was injected via tail vein.  The experiment was terminated 
at 90 min.  After the experiment, blood was collected from the retro-orbital venous sinus 
and immediately combined with (1/5) volume of ACD as an anticoagulant. The platelets 
were counted using a Hemavet 950FS. 
 
Mouse Tail Bleeding Assay 
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C57BL/6 mice were retro-orbitaly injected with IgG (2 mg/kg) or CAN12 (2 mg/kg); 
untreated PAR4-/- mice were used as a control. Ten minutes following injection, tail 
bleeding times were measured by clipping 3 mm from the tip of the tail of anesthetized 
mice. The tail was placed in prewarmed saline at 37°C, and the time to cessation of 
bleeding was measured or the experiment was terminated at 10 min.  The quantity of 
blood loss was determined by lysing the red blood cells in red blood cell lysing buffer, 
measuring the absorbance of hemoglobin at 550 nm, and comparing to a standard curve.  
 
Mouse Saphenous Vein Bleeding Assay 
The method was modified from the previously described protocol by Buyue et al. [240].  
Mice were treated as described for tail bleeding assay.  The saphenous vein was exposed 
in the right hind limb and pierced with a 23-G needle.  Blood was removed around the 
site of injury using a Kimwipe.  After the formation of a clot (~1.5 min), a 1 mm 
longitudinal incision was made using the initial site of injury for entry into the vessel.  
Bleeding was observed for 20 min and each time a subsequent clot formed it was 
disrupted by stroking a needle across the site of injury in the direction of blood flow. The 
average bleeding time was calculated by dividing the total bleeding time by the number 
of clots formed.  In addition, the number of clots formed was recorded.  
 
3.4 Results 
CAN12 reduces the rate of PAR4 cleavage 
The interaction between PAR4 and thrombin is mediated by two sites, the cleavage site 
(L43PAPR) and an anionic region (D57-D65) [164, 165].  The anionic region has a single 
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amino acid change between human and mouse PAR4 (CANDSDTLELPD vs. 
CANDSDTLELPA) suggesting a conserved function.  Therefore, we developed a goat 
polyclonal PAR4 antibody (CAN12) that targets the anionic cluster of PAR4 (Fig. 3.1A) 
[164].  CAN12 interacted with both human (hPAR4) and mouse PAR4 (mPAR4) in 
transfected HEK293 cells (Fig. 3.1B, C).  To determine if CAN12 was specifically 
interacting with the anionic region of PAR4, we transfected 293 cells with hPAR4 or 
hPAR4-AAAA; a construct in which each of the residues in the anionic region is mutated 
to alanine (D57A, D59A, E62A, D65A).  CAN12 did not interact with the mutated 
anionic region (Fig. 3.1 D).  We next determined if CAN12 was able to inhibit PAR4 
cleavage by α-thrombin.  To mirror the expression profile of PARs in human platelets, 
HEK293 cells were cotransfected with HA-PAR1 and V5-PAR4 and the cleavage of 
PAR4 was measured by the disappearance of the N-terminal V5-tag.  CAN12 (2 µg/ml) 
treatment completely inhibited PAR4 cleavage by α-thrombin at 2 min compared to 44.5 
± 6.9% cleavage for the IgG control (2 µg/ml).  Thirty minutes after CAN12 treatment, 
PAR4 cleavage was reduced to 39.4 ± 12.5% compared to 64.5 ± 15.4% for the IgG 
control (Fig. 3.1E, F).  All together these results demonstrate that CAN12 interacts with 
mPAR4 and hPAR4 at the anionic region and is able to slow the rate of PAR4 cleavage. 
 
The effect of CAN12 treatment on human platelet aggregation and secretion 
We next sought to determine if CAN12 is able to inhibit thrombin induced platelet 
aggregation and secretion.  Gel filtered platelets were pretreated with buffer, IgG (2 
µg/ml), or CAN12 (0.2 ng/ml-2 µg/ml) for 10 min at 37°C.  Platelets were stimulated 
with a threshold-dose of α-thrombin (0.5 nM) and the percent aggregation was measured. 
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CAN12 inhibited thrombin induced aggregation in a dose dependent manner with an IC50 
of 10 ng/ml (2-49 ng/ml, 95% CI) (Fig. 3.2A, B).   In contrast, IgG did not influence 
aggregation at a 200 fold higher concentration.  CAN12 also inhibited dense granule 
secretion as measured by ATP release in a dose dependent manner similar to aggregation 
(Fig. 3.2C).  
 
We next examined the influence of CAN12 on platelet aggregation and secretion initiated 
by other agonists (AYPGKF, SFLLRN, ADP, and collagen). PRP was isolated from 
normal healthy donors and treated with buffer, IgG (2 µg/ml), or CAN12 (0.2 ng/ml-2 
µg/ml) for 10 min at 37°C.  High doses of CAN12 (0.02-2 µg/ml) inhibited aggregation 
by the PAR4 agonist peptide, AYPGKF (500 µM), but when the dose was decreased to 2 
ng/ml the percent aggregation returned to 100% (Fig. 3.3A).  This is likely due to the 
large antibody molecule sterically blocking access of AYPGKF to the proposed binding 
site in extracellular loop 2.  In contrast, CAN12 had no effect on aggregation of platelets 
activated with SFLLRN (25 µM) (Fig. 3.3B).  CAN12 dose dependently inhibited ADP 
(5 µM) induced aggregation (Fig. 3.3C). For collagen (1 µg/ml) activated platelets, 
CAN12 inhibited in a dose dependent manner (Fig. 3.3D).  This could be due to PAR4 
having a synergistic effect on collagen activation of GPVI [241]. Interestingly, CAN12 
had no effect on convulxin induced aggregation of platelets (Fig. 3.3E). Similar to 
aggregation, CAN12 inhibited dense granule secretion from platelets activated with 
AYPGKF (500 µM), ADP (5 µM), and collagen (1 µg/ml) (Fig. 3.4 A, C, D). However, 
CAN12 had no effect on secretion induced by SFLLRN (25 µM) and convulxin (5 nM) 
(Fig. 3.4 B, E).   
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CAN12 inhibits aggregation through PAR4 
PAR4 and P2Y12 are known to heterodimerize and these interactions influence the 
function of each receptor [172, 189, 190]. Therefore, we examined if CAN12’s influence 
on ADP-induced aggregation was dependent on PAR4 using platelets isolated from 
PAR4-/- mice.   Washed platelets isolated from wild-type or PAR4-/- mice were pretreated 
with IgG (2 µg/ml) or CAN12 (2 µg/ml) for 10 min at 37°C.  In wild-type mice, 
AYPGKF-induced (500 μM) platelet aggregation of CAN12 treated platelets was reduced 
to 9.3% from 37% for the IgG control (Fig. 3.5A).  As expected, platelets from PAR4-/- 
mice did not respond to AYPGKF (Fig. 3.5B).  Similarly, CAN12 reduced ADP-induced 
aggregation of platelets from wild-type mice from 21% to 8.3%.  Importantly, ADP-
induced aggregation was not influenced in platelets from PAR4-/- mice.  CAN12 also 
appeared to have a slight effect on collagen aggregation; however, the results did not 
reach statistical significance (Fig. 3.5A). These data are in agreement with data from 
human platelets in which CAN12 reduced ADP-induced aggregation.  Further, these data 
demonstrate that inhibitory effects of the antibody are dependent on the presence of 
PAR4. 
 
CAN12 inhibits arterial thrombosis 
Since CAN12 is able to interact with murine PAR4 (Fig. 3.1B) and affect mouse platelet 
activation (Fig. 3.5), our studies determined the ability of CAN12 to affect arterial 
thrombosis in vivo in the Rose Bengal model.  The time to thrombosis was delayed to 
more than 90 minutes when CAN12, 1.0 mg/kg (~14 µg/ml plasma concentration), was 
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injected 10 minutes prior to injury (Fig. 3.6A).  We next wanted to determine the minimal 
dose of CAN12 required to influence the time to thrombosis. The intermediate doses of 
0.5 mg/kg and 0.25 mg/kg had a time to thrombosis of 82 minutes and 60 min, 
respectively.  At 0.125 mg/kg CAN12, the time to occlusion was 37 minutes; the same 
time as the controls (saline and IgG) (Fig 3.6A).  We verified that the delay in thrombosis 
was not due to a decrease in the platelet number (Fig. 3.6B).  Next we investigated 
whether CAN12 prolonged the time to thrombosis when administered after initiation of 
the injury.  For these studies we used the lowest dose of CAN12 (0.5 mg/kg) that 
significantly prolonged the time to occlusion (see Fig. 3.6A).  CAN12 delivered 15 
minutes after injury was able to prolong the time to complete occlusion to 84 minutes 
(Fig. 3.6C).  CAN12 also did not reduce platelet numbers when administered after the 
injury (Fig. 3.6D). Similarly, there was no difference in platelet number between IgG and 
CAN12 treatment when injury was not initiated (425 x 106 ± 56 platelets/ml vs. 462 x 106 
± 90 platelets/ml, respectively). Overall, CAN12 treatment is able to delay arterial 
thrombosis when delivered either before or after injury. 
 
CAN12 does not affect bleeding time 
Finally, we wanted to examine if CAN12 treatment influences hemostasis using two 
assays. The first was the tail clip assay.  C57BL/6 mice were injected with IgG (2 mg/kg) 
or a high dose of CAN12 (2 mg/kg) 10 minutes before the procedure.  There was no 
difference in time to cessation of bleeding or total blood loss between IgG or CAN12 
treated mice (Fig. 3.7A, B).  PAR4-/- mice have a prolonged bleeding phenotype and were 
used as controls [242].  An alternative method for examining the effect of CAN12 on 
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hemostasis was the saphenous vein model.  CAN12 (2 mg/kg) had no effect on the 
bleeding time or number of clot formations compared to the IgG (2 mg/kg) control (Fig. 
3.7C, D).  Similar to the tail clip model, PAR4-/- mice had a prolonged bleeding time and 
fewer clot formations.  Using two independent methods, we demonstrated that CAN12 
treatment does not delay hemostasis in mice. 
 
3.5 Discussion 
In the current study, we have identified the anionic region of PAR4 as a potential 
therapeutic target using an inhibitory antibody.  The antibody is directed toward the 
sequence C54ANDSDTLELPD, which has been identified to be important for PAR4’s 
interaction with thrombin using purified exodomains and cell lines [164, 165, 237].  This 
region is conserved between murine and human PAR4.  A co-crystal with a murine PAR4 
derived peptide and murine thrombin shows that the anionic region of PAR4 makes direct 
contact with thrombin’s autolysis loop [163].  The antibody CAN12 exploits these 
interactions to slow the rate of PAR4 cleavage (Fig. 3.1E and F) resulting in a decrease in 
PAR4 activation.  These data are consistent with published results that demonstrate the 
importance of the anionic region for PAR4 activation by thrombin [164, 165].  By 
interfering with PAR4 activation, CAN12 inhibits thrombin-induced human platelet 
aggregation and thrombosis in the Rose Bengal thrombosis mouse model (Fig. 3.2 and 
3.6).  Importantly, CAN12 does not delay hemostasis in two mouse models.  The studies 
in the current report demonstrate the feasibility of targeting PAR4 in general and, in 
particular, the anionic region of PAR4’s exodomain. 
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Human platelets express two subtypes of protease activated receptors, PAR1 and PAR4, 
which mediate thrombin-induced platelet activation [55, 66, 67].  The interaction and 
subsequent activation of PAR1 and PAR4 by thrombin is mechanistically different.  
PAR1 contains a hirudin-like sequence that binds exosite I of thrombin, which likely 
allosterically induces thrombin into the protease conformation [186].  The net effect is 
efficient activation of PAR1 by low concentrations of thrombin [204, 237].  In contrast, 
PAR4 relies on an anionic cluster (D57, D59, E62, D65), which slows the rate of thrombin 
dissociation and prolongs the interaction time between PAR4 and thrombin [164, 165].   
However, this region does not interact with thrombin’s exosite I and likely does not 
contribute to thrombin allostery, which leads to inefficient PAR4 activation [66, 67].  
However the rate of PAR4 activation is enhanced when it is coexpressed with PAR1 
[165, 184, 185].  We have recently demonstrated that PAR1-mediated enhancement of 
PAR4 cleavage is dependent on PAR1-PAR4 heterodimerization [185].  We have 
previously shown that the anionic cluster contributes to PAR4’s interaction with 
thrombin both in the presence and absence of PAR1 [165].  Therefore, we targeted this 
region for developing a PAR4 antagonist.  The inhibitory antibody, CAN12, was able to 
block thrombin-induced human platelet aggregation in a dose-dependent manner (Fig. 
3.2).  Since PAR1 and PAR4 form homodimers and heterodimers, the antibody, CAN12, 
is likely blocking PAR1 activation due to the interactions of PAR1 and PAR4 on the 
platelet surface as CAN12 does not influence PAR1 activation [183-185, 243]. 
 
The primary focus of thrombin signaling has been directed at PAR1, which has led to the 
development of two PAR1 antagonists that have undergone clinical trials with mixed 
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results.  The most recent clinical trial for a PAR1 antagonist, the vorapaxar TRA-CER 
trial, had to be terminated due to intracranial hemorrhage [136].  PAR4 has received 
much less attention than PAR1.  However, there have been two PAR4 antagonists 
developed, the small molecule YD-3 and the peptide P4pal-10 [244-247].  CAN12 differs 
from these antagonists in two ways.  First, it targets the extracellular anionic region of 
PAR4.  Second, it does not delay hemostasis in mouse models.  This effect is likely due 
to the fact that CAN12 slows the rate of PAR4 activation rather than completely 
inhibiting it. In the arterial thrombosis model in which there is a high flow rate in the 
vessel, the platelets with CAN12 bound will be rapidly cleared from the site of injury 
containing high thrombin concentrations, thus, reducing PAR4 mediated platelet 
activation at the site of injury.  In contrast, in the tail clip and saphenous vein models 
both have a lower flow rate. This may allow the platelets with CAN12 bound to remain in 
proximity of higher thrombin concentrations at the site of injury for a prolonged length of 
time allowing for PAR4 to be cleaved by thrombin and enable platelet activation.  This 
also explains why the bleeding times of the PAR4-/- mice (with zero PAR4 expression) 
are significantly prolonged in both hemostasis assays and the CAN12 treated mice are 
unaffected (Fig. 3.7).  
 
The antibody, CAN12, also affects ADP and collagen-induced human platelet 
aggregation.  The inhibition of ADP induced aggregation is likely through PAR4’s direct 
and indirect interactions with the ADP receptor, P2Y12.  PAR4 and P2Y12 physically 
interact in heterodimeric complexes that directly influence their signaling activities [189, 
190].  In addition, the signaling from the two receptors indirectly influences the activity 
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of one another [172].  CAN12 was able to interfere with collagen-induced aggregation, 
but did not affect a different GPVI agonist, convulxin (Fig. 3.3).  One theory is that 
CAN12 is indirectly affecting collagen-induced aggregation through inhibition of P2Y12 
as previously demonstrated with the P2Y12 antagonist AR-C69931MX, which decreased 
platelet activation by collagen [248].  A second explanation is that CAN12 may be 
sterically interfering with the α2β1 integrin since collagen activates both α2β1 integrin and 
GPVI, whereas convulxin specifically activates GPVI [41, 48, 249, 250].  A third option 
is the size discrepancy between collagen and convulxin. CAN12 could be blocking the 
larger collagen molecule (300 KDa) from interacting with its receptor, but the smaller 
convulxin (72 KDa) can still reach its receptor.  While each of these theories is possible, 
the net effect is that targeting the extracellular domain of PAR4 inhibits human platelet 
aggregation ex vivo and thrombosis in vivo in mice.  Importantly, our experiments with 
PAR4-/- platelets demonstrate the inhibition of ADP induced aggregation is dependent 
upon the presence of PAR4.  Finally, targeting multiple pathways with a single agent can 
be beneficial.  For example, the FDA approved antiplatelet therapy Ticagralor, a non-
competitive P2Y12 antagonist, also influences multiple pathways, which likely 
contributes to its overall effectiveness [251, 252].   
 
The current study demonstrates that targeting the thrombin-binding site away from the 
cleavage site on PAR4 is a viable strategy for antiplatelet therapy.  These studies provide 
justification for developing a humanized monoclonal CAN12 antibody, which is 
currently underway.  The current study also justifies targeting PAR4 for antiplatelet 
therapies in general.  To date, PAR4 has been considered a back-up receptor for PAR1 
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signaling and has been studied less.  However, a recent study has shown that black 
populations have higher levels of microRNA’s that are associated with increased PAR4 
reactivity; PAR1 was unaffected [192].  In this light, PAR4 may be an attractive target 
for specific populations.  Our studies that identify a novel target region on PAR4 provide 
insight toward developing future PAR antagonists based on the mechanism of thrombin 
binding to PAR4.  
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Figure 3.1: CAN12 reduces the rate of PAR4 cleavage. (A) The N-terminus of PAR4 
with C54ANDSDTLELPD (CAN12) and the thrombin cleavage site (*) indicated. (B) 
HEK293 cells (293) or cells transfected with mouse PAR4 (1.0 µg) or human PAR4 (1.0 
µg) blotted with CAN12 (1:100) and actinin (1:1000). (C) Full gel for CAN12 interacting 
with hPAR4 expressed in HEK293 cells. (D) HEK293 cells (293) or cells transfected 
with hPAR4 (4.0 µg) or hPAR4-AAAA (D57A, D59A, E62A, D65A) (4.0 µg) blotted 
with CAN12, PAR4 (C-10), and actinin. (E) HEK293 cells transfected with HA-hPAR1 
(4.0 µg) and V5-hPAR4 (0.1 µg) pretreated with buffer (PAR1PAR4), IgG (2 µg/ml), or 
CAN12 (2 µg/ml) for 10 min at room temperature. The cells were then activated with 
thrombin (100nM) for 0, 2, or 30 min at 37°C. Cleavage of PAR4 was measured by loss 
of the N-terminal V5 epitope. (F) Quantitation of percent of uncleaved PAR4 compared 
to 0 min as 100%. n=4 **p<0.01 vs. time zero  
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Figure 3.1: CAN12 reduces the rate of PAR4 cleavage. 
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Figure 3.2: CAN12 inhibits thrombin induced aggregation and dense granule 
secretion. (A) Gel filtered platelets were isolated from healthy donors. Following 
treatment with goat IgG (2.0 µg/ml) or CAN12 (0.2 ng/ml – 2.0 µg/ml) for 10 min at 
37°C, percent aggregation was determined for thrombin (0.5 nM). Representative curves 
shown. (B) Dose response curve for CAN12 inhibition of thrombin induced aggregation 
(0.5 nM). IC50=10 ng/ml (2-49 ng/ml, 95% CI) (C) Dense granule secretion as 
determined by ATP (nM). *p<0.05 vs. IgG, NS=not significant 
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Figure 3.2: CAN12 inhibits thrombin induced aggregation and dense granule 
secretion. 
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Figure 3.3: CAN12 specificity on aggregation. PRP was isolated from healthy donors. 
Following treatment with goat IgG (2.0 µg/ml) or CAN12 (dose response) for 10 min at 
37°C, percent aggregation was determined for (A) AYPGKF (500 µM), (B) SFLLRN (25 
µM), (C) ADP (5 µM), (D) collagen (1 µg/ml), (E) convulxin (5 nM). Representative 
curves and average percent aggregation shown. *p<0.05 vs. IgG, **p<0.01 vs. IgG, 
NS=not significant 
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Figure 3.3: CAN12 specificity on aggregation. 
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Figure 3.4: CAN12 specificity on dense granule secretion. PRP was isolated from 
healthy donors. Following treatment with goat IgG (2.0 µg/ml) or CAN12 (dose 
response) for 10 min at 37°C, secretion was determined for (A) AYPGKF (500 µM), (B) 
SFLLRN (25 µM), (C) ADP (5 µM), (D) collagen (1 µg/ml), (E) convulxin (5 nM). 
*p<0.05 vs. IgG, **p<0.01 vs. IgG, NS=not significant 
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Figure 3.4: CAN12 specificity on dense granule secretion. 
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Figure 3.5: CAN12 inhibits aggregation through PAR4. Washed platelets were 
isolated from wild-type and PAR4-/- mice.  Following treatment with goat IgG (2.0 
µg/ml) or CAN12(2.0 µg/ml) for 10 min at 37°C percent aggregation was evaluated for 
(A) wild-type and (B) PAR4-/- platelets activated with AYPGFK (500 µM), ADP (5 µM) 
supplemented with 1 mg/ml fibrinogen, or collagen (1 µg/ml). **p<0.01 vs. IgG  
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Figure 3.5: CAN12 inhibits aggregation through PAR4. 
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Figure 3.6: CAN12 inhibits arterial thrombosis.  (A) C57BL/6 mice were pretreated 
with saline, goat IgG (2 mg/kg), or CAN12 (1, 0.5, 0.25, 0.125 mg/kg) for 10 min and 
then subjected to the Rose Bengal carotid artery thrombosis model. Time to complete 
occlusion is indicated or the experiment was terminated at 90 min. (B) The concentration 
of platelets in the blood at termination of the experiment was determined. (C) 15 minutes 
after the initiation of carotid artery thrombosis, C57BL/6 mice were injected with goat 
IgG (2 mg/kg) or CAN12 (0.5 mg/kg) and the time to complete arterial occlusion was 
determined.  The experiment was terminated at 90 min. (D) The concentration of platelets 
in the blood at termination of the experiment was determined. **p<0.01 
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Figure 3.6: CAN12 inhibits arterial thrombosis. 
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Figure 3.7: CAN12 does not affect bleeding time. (A) C57BL/6 mice or PAR4-/- mice 
were anesthetized and 3 mm of the tail was cut.  The time to cessation of bleeding was 
determined or the experiment was terminated at 10 min. (B) The total amount of blood 
loss was determined by reading the absorbance of hemoglobin from lysed red blood cells 
and was compared to a standard curve. (C) C57BL/6 mice or PAR4-/- mice were 
anesthetized and the saphenous vein was exposed and pierced.  Once, bleeding ceased, 
the clot was disrupted. The procedure was repeated for 20 min. The average time of 
bleeding and (D) the number of clot formations were determined. **p<0.01, NS=not 
significant 
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Figure 3.7: CAN12 does not affect bleeding time. 
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Chapter 4 §: 
 
Development and Characterization of Monoclonal Antibodies Against Protease 
Activated Receptor 4 
 
4.1 Abstract 
Background: Protease activated receptor 4 (PAR4) is a G protein coupled receptor 
(GPCR) which is activated by proteolytic cleavage of its N-terminal exodomain. This 
generates a tethered ligand that activates the receptor and triggers downstream signaling 
events. With the current focus in the development of antiplatelet therapies shifted towards 
PARs, new reagents are needed for expanding the field’s knowledge on PAR4. Currently, 
there are no PAR4 reagents which are able to detect activation of the receptor. 
Methods: Monoclonal PAR4 antibodies were purified from hybridomas producing 
antibody that were generated by fusing splenocytes with NS-1 cells. Immunoblotting, 
immunofluorescence, and flow cytometry were utilized to detect the epitope for each 
antibody and to evaluate the interaction of the antibodies with cells. 
Results: Here, we report the successful generation of three monoclonal antibodies to the 
N-terminal extracellular domain of PAR4: 14H6, 5F10, and 2D6. We mapped the epitope 
on PAR4 of 14H6, 5F10, and 2D6 antibodies to residues (48-53), (41-47), and (73-78), 
respectively. Two of the antibodies (14H6 and 5F10) interacted close to the thrombin 
cleavage and were sensitive to α-thrombin cleavage of PAR4. In addition, 5F10 was able 
to partially inhibit the cleavage of PAR4 expressed in HEK293 cells by α-thrombin. 
                                                          
§ A version of this chapter was accepted for publication in the June 2015 issue of Thrombosis Research.  
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Conclusions: These new antibodies provide a means to monitor endogenous PAR4 
expression and activation by proteases on cells. Further, 5F10 will enable experiments 
that specifically block PAR4 activation. 
 
4.2 Introduction 
Protease activated receptors (PARs) are a unique family of seven transmembrane 
receptors, G-Protein Coupled Receptors (GPCRs), that are activated by proteolysis of 
their N-terminus [225].  Once cleaved, the newly exposed N-terminus serves as a tethered 
ligand that activates the receptor by binding extracellular loop 2 [54, 143, 227]. There are 
four members of the PAR family (PAR1-4), which are widely expressed and activated by 
multiple proteases [225, 226].  PARs are capable of initiating signaling through Gi, Gq, 
and G12/13 depending on the activating protease and cellular context [228-232]. PAR1 and 
PAR2 have been the most thoroughly studied, however recent advances have renewed 
interest in PAR4.  
 
The functional roles of PAR4 have primarily been elucidated on platelets. PAR4 is 
traditionally thought of as a low-affinity thrombin receptor that serves as a redundant, 
back up receptor to PAR1. This view is fueled by the overlapping signaling functions of 
PAR1 and PAR4. However, several recent studies demonstrate that PAR4 has distinct 
signaling properties [172, 203, 253]. A key feature that distinguishes PAR4 is its ability 
to form hetero-oligomers with both PAR1 and the ADP receptor P2Y12, which allows 
PAR4 to influence both thrombin and ADP initiated signaling [184, 189, 254, 255]. For 
example, the rate of PAR4 cleavage is significantly enhanced by coexpression of PAR1 
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and PAR4 through hetero-oligomerization [164, 165, 204, 255]. Although it remains to 
be determined if PAR1-PAR4 hetero-oligomers initiate distinct signaling pathways. In 
contrast, the interaction between PAR4 and P2Y12 is directly linked to arrestin-2 
recruitment and AKT signaling [189, 254]. The lateral associations of PAR4 with PAR1 
and P2Y12 place PAR4 at the center of platelet signaling. These interactions take on 
clinical significance in the context of current antiplatelet therapies that target PAR1, 
P2Y12, or both in which case thrombin signaling will be funneled exclusively through 
PAR4 [256]. 
 
It is well known that there are multiple genetic risk factors for cardiovascular disease.  
Among these is a heritable inter-individual variation in platelet reactivity, which is 
greater in black than white individuals [257]. Recent studies directly link these 
differences to PAR4 [191-193]. Edelstein and colleagues provide direct genetic evidence 
for PAR4 by identifying  polymorphisms that change amino acids in PAR4 at positions 
120 (Ala/Thr) and 296 (Phe/Val) [191]. The polymorphism at 120 is common and is 
distributed by race. PAR4-120A exhibited a lower reactivity and was found primarily in 
white individuals, whereas, PAR4-120T was hyper reactive to agonists, resistant to a 
PAR4 antagonist, and found primarily in black individuals. The precise mechanism by 
which these PAR4 mutants effect PAR4 activation still needs to be examined. 
 
Although PAR4 has been primarily studied in platelets, it has physiologic roles in other 
tissues and disease states. PAR4 inhibition has cardioprotective effects against 
myocardial ischemia/reperfusion injury [166]. In rodents, PAR4 has been shown to play a 
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role in joint pain and inflammation [167-169]. In addition, PAR4 expression is enhanced 
in high glucose stimulated human vascular smooth muscle cells [170]. And most recently, 
Pavic and colleagues demonstrated that PAR4 expression was upregulated in diabetes 
and plays a role in diabetic vasculopathy [171]. The sum of these studies demonstrates 
that PAR4 has emerging roles beyond platelets that need to be explored. 
 
Currently, there is a paucity of good reagents for studying PAR4. Here, we report the 
successful generation of three monoclonal antibodies to the extracellular N-terminus of 
PAR4: 14H6, 5F10, and 2D6.  We have mapped the epitope of these antibodies and each 
interacts with a unique region on PAR4.  Two of the antibodies (14H6 and 5F10) interact 
near the thrombin cleavage site and are sensitive to α-thrombin cleavage of PAR4.  
Further, 5F10 partially blocks thrombin cleavage of PAR4. This new panel of PAR4 
antibodies will allow experiments that monitor the expression and activation of PAR4 on 
cells without the use of exogenous epitope tags. These antibodies provide the field with 
essential tools to determine the roles of PAR4 in greater detail. 
 
4.3 Materials and Methods 
Reagents and Antibodies 
Human α-thrombin was purchased from Haematological Technologies (specific activity 
3200-3400 U/mg) (Essex Junction, VT). The secondary antibody IRDYE 800CW donkey 
anti-mouse IgG was purchased from LI-COR Biosciences (Lincoln, NE). HA-Tag (6E2) 
mouse mAB (Alexa Fluor® 647 Conjugate) was purchased from Cell Signaling 
Technology (Beverly, MA). Poly-L-Lysine and fibrinogen were purchased from Sigma-
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Aldrich (St. Louis, MO). VECTASHIELD mounting medium was purchased from Vector 
Laboratories, Inc. (Burlingame, CA). All cell culture reagents, zeocin, hygromycin B, and 
secondary antibodies Alexa Fluor® 647 donkey anti-mouse IgG and Alexa Fluor® 488 
goat anti-mouse IgG were purchased from Invitrogen.  
 
Cell Culture 
NS-1 cells and J7774A.1 cells were grown in HY media (DMEM, NCTC, insulin, 
oxalacetic acid, and pyruvic acid) supplemented with 20% FBS and 1% Penicillin-
Streptomycin.  Flp-In™ T-REx™ 293 cells were purchased from Invitrogen and were 
cultured in DMEM supplemented with 10% fetal bovine serum, 1% Pen/Strep, and 
Zeocin. To generate Flp-In™ T-REx™ 293 cells expressing PAR4, cells were transfected 
with pOG44 vector and pcDNA5/FRT containing PAR4 using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions. Cells stably expressing PAR4 were 
selected with Hygromycin B (200 µg/ml). PAR4 expression was induced with 
tetracycline (1 μg/ml) for 36 hr. 
 
Production and Purification of Recombinant Proteins 
The full-length cDNA for human PAR4 was purchased from UMR cDNA resource 
center. Maltose binding protein-PAR4 fusion proteins (MBP-PAR4(18-78), MBP-
PAR4(41-66), MBP-PAR4(48-72), and MBP-PAR4(54-66) (see Figure 4.1) were 
generated by amplifying the region of interest with PCR and subcloning into pMAL-c2 as 
an EcoRI-HinDIII fragment.  The specific primer sequences are available upon request. 
The MBP-PAR4 fusion proteins were expressed in BL-21 E. coli and were purified by 
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affinity chromatography on an amylose column.  Briefly, the lysate was loaded onto an 
amylose column pre-equilibrated with column buffer (20 mM Tris-HCl pH 7.4, 0.2M 
NaCl, 1mM EDTA) at 4°C. The column was washed with 12 column volumes of column 
buffer, and the protein was eluted in 1 ml fractions with elution buffer (20 mM Tris-HCl 
pH 7.4, 0.2M NaCl, 1mM EDTA, 10 mM maltose).  The concentration of purified protein 
was determined using BioRad protein assay kit. 
 
Animals 
F2RL3-/- mice (referred to as PAR4-/-) were obtained from the Mutant Mouse Regional 
Resource Center (MMRRC) (Chapel Hill, NC). All animal studies were approved by the 
Institutional Animal Care and Use Committee at Case Western Reserve University 
School of Medicine. 
 
Mouse Immunization and Antibody Production 
The method was modified from the previously described protocol by James K. Wahl, III 
[258].  Five week old C57BL/6 F2RL3-/- mice were subcutaneously injected with 150 µg 
of antigen (MBP-hPAR4(18-78)) in complete Freud’s adjuvant. The mice were 
administered 150 µg of antigen via intraperitoneal injections every 2 weeks for 6 weeks. 
Two weeks after the final injection, additional boosts were given daily for three days 
prior to harvesting the splenoctyes. Mouse primary splenocytes were isolated and fused 
with the myeloma cell line NS-1 using polyethylene glycol. The fusion was plated into 96 
well plates and treated the following day with aminopterin to remove unfused NS-1 cells. 
The hybridoma supernatants were screened by immunoblotting against maltose binding 
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protein (MBP) and MBP-PAR4 antigen.  Positive hybridomas were selected by limiting 
dilution and maintained in HY media. 
 
Antibody Purification 
The antibody supernatant was isolated from hybridoma cells by centrifugation (200×g for 
5 min). The supernatant was clarified by centrifuging at 14000×g for 10 min at 4°C. The 
supernatant was loaded onto a Protein A column pre-equilibrated with 20 mM sodium 
phosphate buffer pH 7.0. The column was then washed with 20 mM sodium phosphate 
buffer pH 7.0.  The antibody was eluted from the column with 0.1 M Gylcine-HCl pH 2.5 
and the pH was immediately raised to 8.0 with 1 M Tris pH 9.0. The purified antibody 
was placed in dialysis buffer (0.1 M NaHCO3 pH 8.5, 0.5 M NaCl) overnight. The 
antibody concentration was quantitated using a NanoDrop ND-1000 spectrophotometer 
(molar extinction coefficient 210,000 M-1 cm-1).   
 
Monoclonal Antibody Isotype 
The purified antibodies were diluted (100 ng/ml) and loaded on to isotyping cassettes 
(Thermo Scientific Pierce Rapid Mouse Antibody Isotyping Kit). The isotype for each 
antibody was determined (14H6: IgG2b, kappa; 5F10: IgG2b, lambda; 2D6: IgG1, 
kappa). 
 
Western Blot Analysis 
Immunoblotting was used to determine the epitope for each antibody. MBP, MBP-
PAR4(18-78), MBP- PAR4(41-66), MBP- PAR4(48-72), and MBP-PAR4(54-66) (5 µg) 
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were loaded and resolved by SDS-PAGE and transferred onto nitrocellulose.  The 
membranes were incubated with purified primary monoclonal antibody (anti-MBP, 
14H6, 5F10, or 2D6) for 1 hr. Followed by incubation with secondary antibody IRDYE 
800CW donkey anti-mouse IgG for 1 hr. The membranes were developed using the 
Odyssey Infrared Imaging System.  
 
For HEK293 cells expressing PAR4 and human platelets, the cells were lysed in RIPA 
buffer (1% NP-40, 0.5% Deoxycholate, 0.1% SDS) on ice.  Following lysis, the lysate 
was collected and quantitated using the Biorad DC protein assay. 100µg of total protein 
was loaded and resolved by SDS-PAGE and transferred onto nitrocellulose. The 
membranes were incubated with 50 µg primary antibody (anti-MBP, 14H6, 5F10, or 
2D6) for 1 hr, secondary antibody IRDYE 800CW donkey anti-mouse IgG for 1 hr, and 
developed using the Odyssey Infrared Imaging System. 
 
Flow Cytometry Analysis 
Flp-In™ T-REx™ 293 cells were treated with 1 µg/ml tetracycline for 36 hrs to induce 
expression of HA-PAR4. Cells (2×105) were washed in suspension twice with PBS; some 
cells were treated with α-thrombin (100 nM) for 5 min at 37°C prior to staining.  For 
staining, the cells were incubated in PBS containing 2% BSA and treated with 2 µg of 
primary antibody (14F6, 5F10, 2D6) for 1hr, washed with PBS twice, treated with anti-
mouse 647 secondary antibody (10 µg/ml) in PBS with 2% BSA for 30 min, and washed 
twice with PBS.  The cells were analyzed using the BD LSRFortessa cell analyzer. 
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For measuring the effect of 14H6 and 5F10 on PAR4 cleavage, the experiment was 
carried out the same as described above except the cells were pretreated with 14H6 or 
5F10 (2-50 µg) for 10 minutes and then activated with 100 nM α-thrombin for 5 min at 
37°C. Following activation the cells were labeled with anti-HA-Tag Alexa Fluor 647 (2.5 
µg/ml, clone 6E2, Cell Signaling). Data are expressed as percent cleavage, which was 
calculated by subtracting the mean fluorescence intensity from uninduced cells and 
setting it to 0%.  Induced cells without thrombin were set to 100%. 
 
Human Platelet Isolation 
Human platelets were obtained from healthy donors.  These studies were approved by the 
Case Western Reserve University Institutional Review Board and informed consent was 
obtained from all donors. Whole blood was collected into the anticoagulant acid citrate 
dextrose (ACD) (2.5% sodium citrate, 71.4 mM citric acid, 2% D-glucose) and 
centrifuged at 200×g for 10 minutes at room temperature. The top PRP layer was 
removed and centrifuged at 400xg for 10 minutes at room temperature to pellet the 
platelets.  The platelet pellet was resuspended in HEPES-Tyrode buffer pH 7.4 (10 mM 
HEPES, 12 mM NaHCO3, 130 mM NaCl, 5 mM KCl, 0.4 mM Na2HPO4, 1 mM MgCl2, 
and 5 mM glucose). The number of platelets was quantitated using a Hemavet 950FS 
(Drew Scientific Inc, Waterbury, CT, USA).  
 
Immunofluorescence Microscopy 
Flp-In™ T-REx™ 293 cells adherent to coverslips coated with Poly-L-Lysine were 
treated with 1 µg/ml tetracycline for 36 hrs to induce expression of PAR4. The cells were 
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fixed using 4% formaldehyde, blocked (1% BSA and 40 µg/ml non-immune human IgG 
in PBS), incubated with 20 µg primary monoclonal antibody (14H6, 2D6, 5F10), and 
labeled with secondary antibody (Alexa Fluor® 488 goat anti-mouse IgG). The 
coverslips were mounted on standard glass slides using VECTASHIELD mounting 
medium. For human platelets, washed coverslips were coated with fibrinogen and 
subsequently blocked with 5% BSA in PBS.  0.5 ml of washed human platelets (1 x107 
platelets/ml) in Medium 199 was added to the coverslips and let adhere for 30 min at 
37°C.  The platelets were activated with thrombin (1 nM) for 2 hrs at 37°C. The platelets 
were then treated the same as HEK293 cells described above.  
 
4.4 Results and Discussion 
Generation of PAR4 Monoclonal Antibodies 
Protease activated receptors are activated by cleavage of their N-terminus and antibodies 
targeted to this region have to potential to monitor receptor cleavage and internalization 
on primary cells.  In this study we aimed to generate monoclonal antibodies against the 
N-terminal extracellular domain of PAR4. We used the entire mature exodomain of 
human PAR4 fused to maltose binding protein (MBP) as an antigen (MBP-PAR4(18-78)) 
(Figure 4.1). To maximize the immune response from the MBP-PAR4 fusion protein, we 
used PAR4-/- mice as the host for antibody production. The hybridomas resulting from the 
splenocyte/NS-1 fusion were screened by immunoblotting for MBP and MBP-PAR4(18-
78) simultaneously.  The antibodies that recognized both recombinant proteins were 
discarded as they were directed toward the MBP region of the fusion protein.  
 
131 
 
Identification of the Antibody Epitopes on PAR4 
The initial screening and epitope mapping resulted in antibodies that fell into 3 classes; 
the respective hybridomas were selected by serial dilution and further analyzed. Our 
preliminary screen against a panel of MBP-PAR4 fusion proteins identified three classes 
of antibodies. One antibody from each class (14H6, 5F10, and 2D6) were chosen to map 
the epitope on PAR4 in greater detail (Figure 4.1).  Equal loading on the gel was verified 
by blotting with MBP antibody (Figure 4.2A). 14H6 interacted with MBP-PAR4(18-78), 
MBP-PAR4(41-66), and MBP-PAR4(48-72), but not MBP-PAR4(54-66) indicating that 
the PAR4 antibody 14H6 recognizes residues 48-53 of PAR4 (Figure 4.1, Figure 4.2B). 
5F10 interacted with MBP-PAR4(18-78) and MBP-PAR4(41-66), but not MBP-
PAR4(48-72) or MBP-PAR4(54-66) indicating that the PAR4 antibody 5F10 interacts 
with amino acids 41-47 of PAR4 (Figure 4.1, Figure 4.2C). 2D6 only recognized MBP-
PAR4(18-78) (Figure 4.2D) indicating the epitope is at either end of the PAR4 
exodomain (amino acids 18-40 or 73-78). The epitope was ultimately mapped to amino 
acids 73-78 (see below and Figure 4.3). 
 
Detection of PAR4 Cleavage 
Two of the antibodies (14H6 and 5F10) mapped epitopes near the thrombin cleavage site.  
Antibodies sensitive to PAR4 cleavage by thrombin would be useful reagents to monitor 
endogenous PAR4 activation on cells.  To test if 14H6 and 5F10 recognized cleaved 
PAR4, MBP-PAR4(18-78) was proteolyzed with α-thrombin (100 nM) and the resulting 
MBP-PAR4(18-47) fragment was resolved by SDS PAGE.  Neither 14H6 nor 5F10 
recognized the thrombin cleaved PAR4 indicating that the epitope was disrupted 
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following proteolysis (Figure 4.3).  Our preliminary characterization of 2D6 mapped the 
epitope to either the N-or C-terminus of the PAR4 exodomain (Figure 4.2). The epitope 
was further mapped using thrombin cleaved MBP-PAR4(18-78). Following proteolysis, 
the 2D6 epitope was lost indicating that 2D6 binds C-terminal to the cleavage site; the 30 
amino acid fragment (48-78) is too small to be detected on the gel (Figure 4.3). The 
combined mapping experiments determined the 2D6 epitope to be amino acids 73-78, the 
extreme C-terminus of the PAR4 exodomain. 
 
In this study we focused on α-thrombin activation of PAR4. However, numerous other 
proteases (trypsin, plasmin, cathepsin) also activate PAR4 and therefore, cause platelet 
activation [55, 259, 260]. Plasmin, trypsin, and α-thrombin all cleave PAR4 at Arg47. 
Therefore, 14H6 and 5F10 will be able to detect PAR4 activation by all of the PAR4 
activating proteases in endogenous cells.  
 
Recognition of PAR4 on Cells  
To determine if the antibodies are able to detect PAR4 expressed on cells, we used Flp-
In™ 293 cells engineered to express PAR4 or HA-tagged PAR4 (HA-PAR4) when 
treated with tetracycline (1 μg/ml). 14H6, 5F10, and 2D6 were able to detect PAR4 
expressed on HEK293 cells by immunofluorescence (Figure 4.4A). HA-tag and 
secondary antibody were used as positive and negative controls, respectively. By 
immunoblotting, 14H6 and 5F10 were able to detect PAR4 in HEK293 expressing PAR4 
cells; however, 2D6 was not able to recognize PAR4 (Figure 4.4B). Our mapping studies 
with recombinant proteins show that 14H6 and 5F10 bind near the thrombin cleavage 
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site. We next determined if these antibodies are able to detect the cleavage of PAR4 on 
cells with flow cytometry. The interaction of 14H6 and 5F10 with PAR4 was disrupted 
following activation by α-thrombin (Figure 4.4C). Consistent with previous studies, the 
maximum cleavage of PAR4 was ~50% [255, 261]. Expression of HA-PAR4 was 
confirmed by flow cytometry using a HA-tag antibody.  
  
Recognition of PAR4 on Platelets 
For a more physiological readout we examined if 14H6 and 5F10 were able to detect 
endogenous PAR4 expressed on human platelets. 14H6 and 5F10 both interacted with 
PAR4 expressed in unstimulated human platelets (Figure 4.5A).  Following activation by 
α-thrombin (1, 10, 100 nM), 14H6 and 5F10 were able to detect a decreased level of 
uncleaved PAR4 as a result of the epitope for 14H6 and 5F10 being cleaved from the 
receptor.  This effect was dependent on the concentration of α-thrombin used to activate 
the human platelets.  A similar effect was observed when examining PAR4 expression on 
the surface of human platelets.  Using immunofluorescence, 14H6 was able to detect 
PAR4 expressed on the surface of human platelets and following activation with 
thrombin, there was a decrease in the interaction between PAR4 and 14H6 (Figure 4.5B). 
This indicates that on human platelets, 14H6 and 5F10 only interact with unactivated and 
uncleaved PAR4. 
 
Inhibition of PAR4 Cleavage 
Based on the location of the PAR4 interaction site of 14H6 and 5F10, we investigated if 
the antibodies were able to inhibit PAR4 cleavage.  Flp-In™ 293 cells induced to express 
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HA-tagged PAR4 were pretreated with 14H6 or 5F10 (2-50 µg) and activated with α-
thrombin (100 nM) for 10 min; loss of the N-terminal HA-tag was used as the readout for 
detecting PAR4 cleavage. To quantify the amount of PAR4 cleavage, background 
staining from uninduced cells was subtracted from all samples (Figure 4.6). The antibody 
14H6 did not interfere with thrombin cleavage up to 50 μg total antibody. However, 5F10 
was able to partially inhibit PAR4 cleavage at 50 μg total antibody. These data are 
consistent with our mapping studies in which 5F10 mapped to the P7-P1 residues 
(nomenclature of Schecter and Berger [205]) corresponding to Ser41 to Arg47 that are 
important for thrombin recognition of its substrates [188, 262]. In contrast, 14H6 maps to 
P1’-P7’ residues (Gly48-Val53).  We have previously described an antibody to PAR4 that 
blocks platelet thrombin-induced activation of human platelets and delays thrombosis in 
mouse models in vivo [261]. Therefore we tested the ability of 14H6 and 5F10 to block 
human platelet activation. Neither 14H6 nor 5F10 were able to block thrombin-induced 
aggregation at concentrations up to 10 μg/ml. The most plausible explanations for these 
results are that 14H6 and 5F10 bind with an affinity that is too low to overcome PAR1 
activation, which is also present on the platelet surface. 
 
4.5 Conclusions 
In the current study, we generated three classes of monoclonal antibodies that recognize 
unique regions on human PAR4. Two of the antibodies (14H6, 5F10) were able to detect 
PAR4 expression in HEK293 cells by immunoblotting, immunofluorescence, and flow 
cytometry and were found to be sensitive to PAR4 activation. In addition, 5F10 could 
partially inhibit PAR4 cleavage by α-thrombin. Importantly, 14H6 and 5F10 were able to 
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detect endogenous PAR4 expression in human platelets. The third antibody, 2D6, was 
able to detect PAR4 expressed on cells by immunofluorescence microscopy. The studies 
described in this current report demonstrate the development of three useful tools for 
advancing our understanding of PAR4 in platelets and less well studied tissues. 
 
In studies moving forward examining genetic variations of PAR4 in human platelets and 
the role of PAR4 in other tissues, these antibodies provide novel tools, which provide the 
invaluable ability to detect PAR4 in endogenous tissues/cells and to measure the initial 
step in PAR4 activation, PAR4 cleavage. These antibodies fill a gap in the currently 
available reagents for examining PAR4 and enable further advances in understanding the 
function and role of PAR4 in newly appreciated tissues and disease conditions. 
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Figure 4.1: Schematic of PAR4 extracellular constructs fused to MBP. PAR4 
extracellular fragments were subcloned into pMAL-C2 to generate MBP-PAR4(18-78), 
MBP-PAR4(41-66), MBP-PAR4(48-72), and MBP-PAR4(54-66), which were used for 
generating and screening PAR4 monoclonal antibodies. The interaction for each antibody 
is illustrated. 
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Figure 4.1: Schematic of PAR4 extracellular constructs fused to MBP. 
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Figure 4.2: Characterization of extracellular PAR4 interaction sites. E. coli were 
transformed, cultured, lysed, and the fusion proteins (MBP, MBP-PAR4(18-78), MBP-
PAR4(41-66), MBP-PAR4(48-72), and MBP-PAR4(54-66)) were purified by affinity 
chromatography. The epitopes for each PAR4 monoclonal antibody were determined by 
immunoblotting. (A) Control blot with MBP to show that all of the recombinant PAR4 
sections were purified and are present on the gel. (B) 14H6 interacted with MBP-
PAR4(18-78), MBP-PAR4(41-66), and MBP-PAR4(48-72) protein fragments. (C) 5F10 
recognized MBP-PAR4(18-78) and MBP-PAR4(41-66). (D) 2D6 interacted with only the 
complete extracellular section, MBP-PAR4(18-78). 
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Figure 4.2: Characterization of extracellular PAR4 interaction sites. 
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Figure 4.3: Monoclonal antibodies detect PAR4 cleavage by thrombin. The full 
exodomain of PAR4 (MBP-PAR4(18-78)) was cleaved with  100 nM α-thrombin (IIa) 
for 5 min and immunoblotted with 14H6 or 5F10 to determine if they recognize cleaved 
PAR4. The cleaved PAR4 exodomain was used to further map the 2D6 epitope to 
residues 73-78. 
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Figure 4.3: Monoclonal antibodies detect PAR4 cleavage by thrombin. 
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Figure 4.4: Detection of PAR4 on HEK293 cells. Following induction of Flp-In™ T-
REx™ 293 cells with tetracycline (1 µg/ml) for 36 hrs, (A) immunofluorescence and (B) 
immunoblotting were used to determine the ability of 14H6, 5F10, or 2D6 to interact with 
PAR4 on cells. HA was used as a positive control. Secondary antibody was used a 
negative control. (C) Flow cytometry was used to evaluate the ability of 14H6, 5F10, and 
2D6 to interact with uncleaved HA-PAR4 and cleaved HA-PAR4 (100 nM α-thrombin 
(IIa)) on cells. HA-PAR4 induction was determined using a HA-tag specific antibody. 
Mouse IgG was used as a negative control.  
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Figure 4.4: Detection of PAR4 on HEK293 cells. 
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Figure 4.5: Detection of PAR4 on platelets. (A) Human platelets (hPLT) were activated 
with α-thrombin (0, 1, 10, 100 nM) for 5 min at 37°C, lysed, and immunoblotted with 
14H6 and 5F10 (50 µg). HEK293 cells were used as a negative control. (B) 
Immunofluorescence examining the interaction of 14H6 (20 µg) with unstimulated and α-
thrombin (1 nM) stimulated human platelets. 
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Figure 4.5: Detection of PAR4 on platelets. 
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Figure 4.6: Inhibition of PAR4 cleavage. Flp-In™ T-REx™ 293 cells were induced 
with tetracycline (1 mg/ml) for 36 hrs to express HA-PAR4.  Following induction cells 
were treated with buffer, 14H6, or 5F10 (2-50 µg) for 10 min and activated with α-
thrombin (100 nM) for 5 min at 37°C. Cleavage of PAR4 was measured by loss of an N-
terminal HA-tag. % uncleaved PAR4 was normalized to not induced, not activated, and 
buffer pretreatment (0%) and induced, not activated, and buffer pretreatment (100%). 
**p<0.01 
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Figure 4.6: Inhibition of PAR4 cleavage. 
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Chapter 5 : Discussion and Future Directions 
Together the studies described in this body of work provide the framework to further 
understand how PAR1 and PAR4 interact and influence the function of one another.  
Through three independent studies it was shown that PAR1 and PAR4 form a α-thrombin 
dependent heterodimer that affects PAR4 activation, that the anionic cluster on PAR4 
could be a new viable target to antiplatelet therapy, and that three PAR4 monoclonal 
antibodies that interact with unique regions on the receptor were developed.  Each study 
is discussed in detail below and future experiments are proposed. 
 
Chapter 5.1: PAR1-PAR4 Heterodimerization 
In Chapter 2 we report our findings on the formation of PAR1-PAR4 heterodimers.  This 
study determined that the formation of a heterodimer composed of PAR1 and PAR4 is 
dependent on cleavage of both receptors by α-thrombin. The heterodimer interface was 
mapped to four resides in transmembrane helix 4 from both PAR1 and PAR4. Finally, it 
was determined that PAR1 assisted PAR4 cleavage is disrupted when heterodimer 
formation is inhibited. Overall, these studies have characterized PAR1-PAR4 
heterodimer formation and show the functional significance of heterodimer formation. 
 
Bioluminescence resonance energy transfer (BRET) was utilized to examine heterodimer 
formation on living cells with minimal expression levels to avoid overexpression 
artifacts. Using HEK293 cells it was shown that only following cleavage by α-thrombin 
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would PAR1-PAR4 heterodimers form.  Coimmunoprecipitiation was used to show that 
PAR1 and PAR4 form heterodimers which agrees with previously published studies by 
Leger et al [184].  For the current CO-IP experiments and past CO-IP experiments, 
activation with α-thrombin was not necessary for dimer formation. However, these 
experiments were performed in a different cell culture model (COS-7 cells) and required 
high expression levels of PAR1 and PAR4 (10-fold higher than BRET studies). Based on 
previous studies demonstrating that PAR1 and PAR4 coimmunopreciptiate in human 
platelets following stimulation with α-thrombin and the current studies, α-thrombin 
stimulation is necessary for PAR1-PAR4 heterodimerization [184]. 
 
While in this study it was determined that PAR1-PAR4 heterodimer formation is specific 
to activation with α-thrombin, it has previously been determined that PAR1 and PAR4 
also form constitutive homodimers [182, 183]. In addition, these studies show that the 
same residues are necessary for both PAR4 homodimer formation and PAR1-PAR4 
heterodimer formation.  This suggests a balance between monomers, homodimers, and 
heterodimers.  PAR1 and PAR4 monomers, homodimers, and heterodimers may play a 
specific role in regulating different signaling events.  In the case of the PAR activation 
peptides which do not induce heterodimerization, they could be activating different 
signaling events compared to cleavage by α-thrombin.  A current study is underway 
examining differences in the phosphoproteome of human platelets stimulated with PAR 
activation peptides versus α-thrombin. 
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It has previously been determined that localization of PAR1 in the plasma membrane in 
endothelial cells is determined by the protease activating the receptor [154-156].  
Currently, limited data is available about the location of PAR1 and PAR4 in platelet 
membranes and the role that lipids play in PAR activation and signaling.  Preliminary 
data suggests that PAR1 and PAR4 are excluded from limited rafts in platelets (data not 
shown). Future studies will have to examine in more detail if PARs are located in lipid 
rafts on platelets and if activation with different proteases and activation peptides 
influence their localization and signaling. 
 
Overall, this study shows that PAR1 and PAR4 form heterodimers that are necessary for 
PAR1 assisted PAR4 cleavage.  With the recent approval of vorapaxar, PAR1 antagonist, 
as an antiplatelet therapy, future studies will need to expand on what effect 
heterodimerization has on PAR activation and signaling and what effect vorapaxar has on 
heterodimerization.  Also further studies examining the molecular arrangements on PARs 
on human platelets will aid in the development of further antiplatelet therapies. 
  
Chapter 5.2: The N-terminus of PAR4 as an Antiplatelet Therapy Target 
While many different approaches are available for treating and preventing acute coronary 
syndromes (ACS), there is currently an unmet need for antiplatelet therapies that inhibit 
thrombosis without significantly increasing bleeding risk. In Chapter 3, I discussed the 
findings that demonstrate that the anionic cluster (D57, D59, E62, D65) on the N-terminus of 
PAR4 is a new potential antiplatelet therapy target. A goat polyclonal antibody (CAN12) 
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was developed that specifically interacts with the anionic cluster allowing it to delay 
cleavage of PAR4. CAN12 was able to block thrombin-induced human platelet 
aggregation and secretion in a dose-dependent manner.  In addition, when administered 
before or after injury CAN12 was able to prevent carotid artery thrombosis in mice. 
Importantly, CAN12 treatment did not influence hemostasis in two independent mouse 
models. 
 
PAR1 and PAR4 are both expressed on human platelets and are responsible for 
regulating thrombin induced platelet activation [55]. PAR1 is activated by lower 
concentrations of thrombin while PAR4 requires higher concentrations of thrombin to be 
activated [66, 164, 165]. However, the rate of PAR4 activation is enhanced in the 
presence of PAR1, and heterodimerization of the two receptors is necessary for PAR1-
mediated enhancement of PAR4 cleavage [185]. Additionally, PAR1 and PAR4 have 
been previously shown to form homodimers [182, 183]. Since CAN12 was shown to 
specifically interact with the anionic cluster on PAR4 and dose-dependently inhibit 
thrombin-induced human platelet aggregation, and not inhibit PAR1 activation by 
SFLLRN, CAN12 must be inhibiting both PAR1 and PAR4 activation through the 
interactions of the receptors on the platelet surface. However, the exact mechanism of 
inhibition and the arrangement of PAR1, PAR4, thrombin, and CAN12 need to be 
examined in future studies. While it was beyond the scope of the current study different 
approaches to examine exact mechanism of inhibition could be (1) examining if PAR1 
and PAR4 inhibition is dimer dependent on platelets, (2) what type of complex is formed 
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in the presence of purified PAR1, PAR4, thrombin, and CAN12, and (3) does 
inhibition/activation affect localization of the receptors on platelets (i.e. lipid rafts). 
 
In addition to affecting thrombin induced platelet aggregation and secretion, CAN12 also 
affected ADP-induced human platelet aggregation. Since CAN12’s effect on ADP 
induced aggregation was PAR4 dependent, CAN12 was mostly likely able to inhibit ADP 
induced aggregation through PAR4’s direct and indirect interactions with the ADP 
receptor, P2Y12 [172, 189, 190].  This is of note since the current standard of care for 
ACS includes a P2Y12 antagonist.  If targeting the anionic cluster on PAR4 inhibits both 
ADP and thrombin induced aggregation, it could be used as an alternative to combination 
therapy. 
 
For our in vivo studies we utilized mice as our animal model. Mice have a different 
expression profile of PARs on their platelets compared to humans [55, 67, 162].  On 
human platelets, both PAR1 and PAR4 are responsible for signaling and inducing platelet 
aggregation by thrombin, but on mouse platelets PAR4 cleavage is necessary for platelet 
activation by thrombin. PAR3 does not signal. While it is important to consider species 
differences in PAR expression on platelets, the effect of CAN12 on thrombosis and 
hemostasis in human platelets is likely to be similar to murine platelets.  This is due to the 
fact that CAN12 was able to inhibit thrombin induced aggregation of human platelets 
through PAR1 and PAR4 and aggregation of murine platelets mediated by PAR4. 
 
154 
 
It should be noted that inhibition with CAN12 had differing effects on hemostasis 
compared to knocking-out PAR4 in mice (PAR4-/-). PAR4-/- mice have a prolonged time 
to thrombosis and have significantly increased bleeding times.  By comparison, inhibiting 
PAR4 prolonged thrombosis but did not affect the time to hemostasis.  This is likely due 
to the fact that CAN12 slows the rate of PAR4 activation rather than completely 
inhibiting it. One hypothesis for this phenomenon is that in the case of arterial thrombosis 
where there is a high flow rate in the vessel, the platelets with CAN12 bound will be 
rapidly cleared from the site of injury containing high thrombin concentrations, allowing 
reduced PAR4 mediated platelet activation at the site of injury.  In contrast, in a venous 
blood vessel there is a lower flow rate that would allow the platelets with CAN12 bound 
to remain in proximity of higher thrombin concentrations at the site of injury for a 
prolonged length of time. PAR4 would then be able to be cleaved by thrombin and induce 
platelet activation. Future studies using flow chambers could be utilized to elucidate the 
effect of flow rate on CAN12 mediated inhibition of platelet activation. 
 
Overall, the current study demonstrates the feasibility of targeting the anionic cluster on 
PAR4 as an antiplatelet therapy strategy and provides justification to generate a 
monoclonal antibody targeting the anionic cluster on PAR4.  After confirming that a 
monoclonal antibody has similar specificity and effect on aggregation, thrombosis, and 
hemostasis, it could then be humanized. Ideally, the antibody could be humanized with 
little effect on its affinity for the anionic cluster on PAR4.  The development of Fab 
fragments and single-chain antibodies would be an alternate approach to decrease the 
immune response; however, this would sacrifice half-life since they have a lower 
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molecular mass and tissue permeability is not an issue since we are targeting cells in 
circulation, platelets. Thus while our studies provide the framework for the development 
of a PAR4 inhibitory antibody that inhibits thrombosis without affecting hemostasis, it 
will require greater in depth efforts to expand targeting PAR4 as an antiplatelet therapy.  
 
Current studies by other labs with different approaches for targeting PAR4 (indole 
derived PAR4 antagonists such as ML354, the small molecule YD-3, and the peptide 
P4pal-10) are in progress [244-247, 263, 264].  In contrast to other labs’ approaches, I 
hypothesize that using a monoclonal antibody as a therapy is ideal for our target.  
Because PAR4 is expressed on the surface of platelets in circulation, a monoclonal 
antibody will enable us to target PAR4 on platelets while preventing off target effects on 
other tissues since monoclonal antibodies have limited tissue permeability. In addition, 
monoclonal antibodies have less variability in the plasma concentration at a given dose 
between patients. This can be compared to metabolism of small molecules that can vary 
more on an individual patient basis. Finally, the half-life of monoclonal antibodies is 
longer than those of small molecule agents.  Ideally, this will enable weekly dosing of 
antibody therapy compared to daily dosing of small molecule treatment. 
 
Chapter 5.3: PAR4 Monoclonal Antibodies 
 To expand upon the studies in Chapter 3, three monoclonal antibodies (14H6, 5F10, 
2D6) which interact with PAR4 were developed.  Using purified sections of PAR4, the 
epitope for each antibody was mapped and all three interacted with a unique region on 
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the N-terminus of PAR4.  2D6 was found to interact with both cleaved and uncleaved 
PAR4.  14H6 and 5F10 were determined to only interact with uncleaved PAR4 since 
their epitope is close to the thrombin cleavage site on the receptor. 14H6 and 5F10 were 
able to detect endogenous PAR4 expression in human platelets. In addition 5F10 was 
found to be able to partially inhibit PAR4 cleavage, but only using a large quantity (500 
µg/ml) of antibody. The third antibody, 2D6, was able to detect PAR4 expressed on cells 
by immunofluorescence microscopy.  These studies lead to the development of three 
novel tools to advance the field’s understanding of PAR4 in platelets and other 
endogenous cells and tissues. 
 
The ultimate goal when this project began was to develop a monoclonal antibody that 
interacted with the anionic cluster (C54ANDSDTLELPD) on the N-terminus of PAR4.  
Through a myriad of approaches using different immunogens (MBP-PAR4(18-78), MBP-
PAR4(48-72), MBP-PAR4(54-66), IgG-PAR4(54-66), KLH-PAR4(54-66)) I was 
unsuccessful in generating a monoclonal PAR4 antibody that interacted with the anionic 
cluster on PAR4.  However, these studies provide the ability to understand in more detail 
the importance of targeting the anionic cluster versus other locations on the N-terminus 
of PAR4 to inhibit platelet activation. Since 14H6 and 5F10 both target close to the 
thrombin cleavage site on the N-terminus but not the anionic cluster, these antibodies 
were utilized to examine the effect of targeting close to the thrombin cleavage site on 
human platelet aggregation. Neither 14H6 nor 5F10 were able to block thrombin-induced 
aggregation at concentrations up to 10 μg/ml (data not shown). CAN12 was able to 
completely inhibit thrombin induced aggregation of human platelets at a concentration of 
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0.2 μg/ml.  These results suggest that targeting the anionic cluster on PAR4 provides a 
unique effect of inhibiting platelet aggregation by thrombin through inhibiting both 
PAR1 and PAR4.  Without inhibiting PAR1, human platelets are able to be activated by 
thrombin and PAR1 can still enhance PAR4 cleavage. It is also possible that targeting the 
PAR4 cleavage site is not a viable option because thrombin has a higher affinity for the 
cleavage site than 14H6 and 5F10. Another option is 14H6 and 5F10 have significantly 
lower affinity for PAR4 versus CAN12.  With current studies underway to purify 
recombinant human PAR4, we will be able to examine the affinity that each antibody has 
for the purified receptor. The antibody affinity can be compared to the affinity of 
thrombin for purified PAR4. As a starting point, the affinity of thrombin for purified 
PAR4 can be compared to the previously published affinity of thrombin for purified 
PAR4 exodomain (61 µM). 
 
The incidence and severity of cardiovascular disease is dictated by numerous factors 
including medical adherence, environmental exposures, and genetic polymorphisms 
[265]. When looking at the genetic component, black individuals develop cardiovascular 
disease at a younger age and have a higher incidence of mortality from the disease. This 
correlates with a heritable interindividual variation in platelet reactivity observed to be 
higher in self-identified black individuals than white individuals [194-196]. Recent 
studies were able to directly link the differences in platelet reactivity to PAR4, 
specifically polymorphisms at positions 120 (Ala/Thr) and 296 (Phe/Val) [191-193]. 
While these polymorphisms have been found to correlate with PAR4 reactivity, the exact 
mechanism of how they affect PAR4 needs to be examined.  The newly developed 
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antibodies will aid in studies investigating the influence of the polymorphisms on PAR4 
activation.  Specifically, they will enable detection of varying expression levels of PAR4 
in platelets from individuals with different polymorphisms, measuring the effect that 
different polymorphisms have on the rate of PAR4 activation (cleavage), and examining 
what effect current antiplatelet therapies (ADP antagonist, PAR1 antagonist) have on 
PAR4 activation in relation to the different polymorphisms. 
 
Human platelets express two thrombin receptors, PAR1 and PAR4, and the two receptors 
have distinct signaling properties [172, 203, 253]. A key feature that distinguishes PAR4 
is its ability to influence both thrombin and ADP initiated signaling through the 
formation of hetero-oligomers with both PAR1 and the ADP receptor P2Y12 [184, 189, 
190].  Because current antiplatelet therapies inhibit both PAR1 and P2Y12 signaling, 
PAR4 takes on a central role in both influencing the effectiveness of therapy and 
becoming the primary mediator of thrombin signaling. With the current antiplatelet 
therapies funneling platelet activation through PAR4 the field needs to expand the limited 
understanding of PAR4. The newly developed antibodies will help enable these studies.  
 
Even though PAR4 has been primarily studied in platelets, it also plays a role in other 
tissues and disease states.  PAR4 inhibition has been previously shown to have 
cardioprotective effects against myocardial ischemia/reperfusion injury [166]. PAR4 has 
also been shown to play a role in joint pain, inflammation, and diabetic vasculopathy 
[167-169, 171]. In addition, PAR4 expression is increased in high glucose stimulated 
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human vascular smooth muscle cells [170]. These antibodies will enable further 
expansion of these studies in endogenous cells and tissue and will enable examining 
PAR4 activation directly. 
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